Dacomitinib
A7471058
Final Protocol, 14 November 2018
Page 1
A PHASE 1, OPEN-LABEL, SINGLE-DOSE, PARALLEL-GROUP STUDY TO 
EVALUATE THE PLASMA PHARMACOKINETICS AND SAFETY OF 
DACOMITINIB IN PARTICIPANTS WITH SEVERELY IMPAIRED HEPATIC 
FUNCTION RELATIVE TO PARTICIPANTS WITH NORMAL HEPATIC 
FUNCTION
Investigational Product Number: PF-00299804
Investigational Product Name: Dacomitinib
United States (US) Investigational New 
Drug (IND) Number:
European Clinical Trials Database 
(EudraCT) Number:Not Applicable
Protocol Number: A7471058
Phase: 1
Short Title: Hepatic Impairment StudyCCI
Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 2Protocol Amendment Summary of Changes Table
Document History
Document Version Date Summary of Changes and Rationale
Original Protocol 14November 2018 Not applicable (N/A)

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 3TABLE OF CONTENTS
LIST OF TABLES .....................................................................................................................7
1.PROTOCOL  SUMMARY .....................................................................................................8
1.1. Sy nopsis ....................................................................................................................8
1.2. Schema ......................................................................................................................8
1.3. Schedule 
of Activities (SoA) .....................................................................................9
2. INTRODUCTION ...............................................................................................................12
2.1. Study  Rationale .......................................................................................................12
2.2. Background .............................................................................................................13
2.2.1. Nonclinical Pharmacology ..........................................................................13
2.2.2. Nonclinical Pharmacokinetics and Metabolism
.........................................14
2.2.3. Nonclinical Safet y
......................................................................................14
2.2.4. Clinical Overview .......................................................................................15
2.3. Benefit/Risk Assessme nt
.........................................................................................16
3. OBJECTI
VES AND EN DPOINTS .....................................................................................17
4. STUDY DESIGN .................................................................................................................17
4.1. Ove rall Design .........................................................................................................17
4.2. Scientific Rationale for Study  Design .....................................................................19
4.3. Justification for Dose ..............................................................................................20
4.4. End of Study  Definition ..........................................................................................20
5. STUDY POPUL ATION
......................................................................................................21
5.1. I nclusion Criteria .....................................................................................................21
5.1.1. All Participants
...........................................................................................21
5.1.2. Additional I nclusion Criteria for Participants with Normal Hepatic 
Function (Cohort 2)
..........................................................................................21
5.1.3. Additional I nclusion Criteria for Participants with Severely  Impaired 
Hepatic Function (Cohort 1) ............................................................................22
5.2. Exclusion Criteria ....................................................................................................23
5.2.1. All Participants
...........................................................................................23
5.2.2. Additional Exclusion Criteria for Participants with Normal Hepatic 
Function (Cohort 2) ..........................................................................................24

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 45.2.3. Additional Exclusion Criteria for Participants with Severely  
Impaired Hepatic Function (Cohort 1) .............................................................24
5.3. L ifesty le Considerations ..........................................................................................26
5.3.1. Meals and Dietary  Restrictions ...................................................................26
5.3.2. Caffeine, Alcohol, and Tobacco .................................................................26
5.3.3. Activity .......................................................................................................27
5.3.4. Contraception ..............................................................................................27
5.4. Screen Failures ........................................................................................................27
6. STUDY INTERVENTIO N
..................................................................................................28
6.1. Study  Intervention Administered ............................................................................28
6.1.1. Administration ............................................................................................28
6.2. Preparation/Handling/Storage/Accountability ........................................................28
6.2.1. Preparation and Dispensing ........................................................................29
6.3. Measures to Minimize Bias: Randomization and Blinding .....................................30
6.3.1. Allocation to I nvestigational Product .........................................................30
6.4. Study  Intervention Compliance ...............................................................................30
6.5. Concomitant Therapy ..............................................................................................30
6.6. Dose Modification ...................................................................................................30
6.7. I ntervention After the End of the Study ..................................................................31
7. DI SCONTINUATION O F STUDY 
INTERVENTION AND PARTI CIPANT 
DISCONTINUATION/WI THDRAWAL ...........................................................................31
7.1. Discontinuation of Study  Intervention ....................................................................31
7.2. Participant Discontinuation/Withdrawal From the Study .......................................31
7.3. L ost to Follow up ................................ ................................ ................................ ....32
8. STUDY ASSESSMENTS AND PROCEDURES ................................ ............................... 32
8.1. Efficacy  Assessments ..............................................................................................33
8.2. Safet y Assessments .................................................................................................33
8.2.1. Phy sical Examinations ................................................................................34
8.2.2. Vital Signs ..................................................................................................34
8.2.3. Electrocardiograms
.....................................................................................34
8.2.4. Clinical Safety  Laboratory  Assessments ....................................................35
8.3.
Adverse Events and Serious Adverse Events..........................................................36

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 58.3.1. Time Period and Frequency  for Collecting AE and SAE Information .......36
8.3.1.1. Reporting SAEs to Pfizer Safety ...............................................37
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF
...................37
8.3.2. Method of Detecting AEs and SAEs ..........................................................37
8.3.3. Follow -up of AEs and SAEs .......................................................................37
8.3.4. Regulatory
 Reporting Requirements for SAEs ...........................................38
8.3.5. Exposure During Pregnancy  or Breastfeeding, and Occupational 
Exposure ..........................................................................................................38
8.3.5.1. Exposure During Pregnancy ......................................................38
8.3.5.2. Exposure During Breastfeeding ................................................38
8.3.5.3. Occupational Exposure .............................................................39
8.3.6. Medication Errors .......................................................................................39
8.4. Treatment of Overdose
............................................................................................40
8.5. Pharmacokinetics ....................................................................................................40
8.5.1. Pha rmacokinetic Assessment of Dacomitinib and PF -
05199265...............40
8.5.2. Protein Binding Assessment .......................................................................41
8.6. Pharmacod ynamics ..................................................................................................41
8.7. Genetics ...................................................................................................................42
8.7.1. CYP2D6 Genoty ping Analy sis...................................................................42
8.7.2. Banked Bios
pecimens for Genetics ............................................................42
8.8. Biomarkers ..............................................................................................................42
8.9. Health Economics ...................................................................................................42
9. STATI STICAL CONSI DERATIONS
................................................................................43
9.1. Statistical Hy potheses .............................................................................................43
9.2. Sample Size Determination .....................................................................................43
9.3. Populations for Analysis .........................................................................................43
9.4. Statistical Analy ses.................................................................................................43
9.4.1. Efficacy  Anal yses................................ ................................ ....................... 43
9.4.2. Safet y Anal yses................................ ................................ .......................... 43
9.4.2.1. Electrocardiogram Analy ses......................................................44
9.4.3. Other Anal yses............................................................................................44
9.4.3.1. Pharmacokinetic Analy ses........................................................44

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 69.4.3.2. Pharmacod ynam ic Anal yses.....................................................45
9.5. I nterim Anal yses.....................................................................................................45
9.5.1. Data Monitoring Committee .......................................................................45
10. SUPPORTING DOCUM ENTATION A ND OPERATI ONAL 
CONSI DERATIONS
..........................................................................................................46
10.1. Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ...............46
10.1.1. Regulatory and Ethical Considerations ....................................................46
10.1.1.1. Reporting of Safety  Issues and Serious Breaches of the 
Protocol or I CH GCP .........................................................................46
10.1.2. F inancial Disclosure .................................................................................47
10.1.3. I nformed Consent Process ........................................................................47
10.1.4. Data Protection .........................................................................................48
10.1.5. Dissemination of Clinical Study  Data ......................................................49
10.1.6. Data Qualit y Assurance ............................................................................50
10.1.7. Source Documents ....................................................................................51
10.1.8. Study  and Site Closure ..............................................................................51
10.1.9. Publication Policy
.....................................................................................52
10.1.10. Sponsor’s Qualified Medical Personnel .................................................53
10.2. Appendix 2: Clinical Laboratory  Tests .................................................................54
10.3. Appendix 3: Adverse E vents: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting ......................................................................55
10.3.1. Definition of AE .......................................................................................55
10.3.2. Def inition of SAE .....................................................................................56
10.3.3. Recording/Reporting and Follow
-up of AEs and/or SAEs .......................57
10.3.4. Reporting of SAEs
....................................................................................60
10.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information ................................................................................................................62
10.4.1. Male Participant Reproductive Inclusion Criteria
....................................62
10.4.2. Female Participant Reproductive Inclusion Criteria .................................62
10.4.3. Woman of Childbearing Potential (WOCBP) ................................ .......... 62
10.4.4. Contraception Methods ................................ ................................ ............. 63
10.5. Appendix 5: Genetics ............................................................................................67
10.6. Appendix 6: Liver Safety : Suggested Actions and Follow -up Assessments ........68

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 710.7. Appendix 7: ECG Findings of Potential Clinical Concern ...................................70
10.8. Appendix 8: Modified Child -Pugh Classification (CPC) of L iver 
Dysfunction ...............................................................................................................72
10.9. Appendix 9: Abbreviations
...................................................................................73
11. REFERENC ES..................................................................................................................76
LIST OF TABLES
Table 1.
Hepatic Function Categories Based on Child- Pugh Classification ......................18
Table 2. Protocol -Required Safet y Laboratory  Assessments .............................................54

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 81.PROTOCOL SUMMARY
1.1.Synopsis
Not applicable.
1.2.Schema
Not applicable.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 91.3.Schedule of Activities (SoA)
The SoA tableprovides an overview of the protocol visits and procedures.  Refer to the STUDY ASSESSMENTS AND 
PROCEDURES section of the protocol for detailed information on each procedure and assessment required for compliance with the 
protocol. 
The investigator may  schedule visits (unplanned visits) in addition to those listed in the SoA table, in order to conduct evaluations or 
assessments required to protect the well-being of the participant.
Visit IdentifieraScreeningbStudy Period Follow Ups
or Early 
TerminationtDays Relative to Day 1 Day -28 to 
Day -2Day -1 Day 1 Day 
2Day 
3Day 
4Day 
5Day 
6Day 
7Day 
8Day 
9Day 
10Day 
12
Hours After Dose 0246812 24 48 72 96 120 144 168 192 216 264
Informed consent X
CRU confinementcX           X
Revie w inclusion/exclusion 
criteriaX X
Dem ographydX
Medical/medication history 
(update)eX X
Physical exam ination , 
height, and body weightfX X X Xt
Safety laboratory testsgX X X X Xt
Contraception checkhX X Xs,t
Alcohol/tobacco use & 
Breath alcohol testiX X
FSH (only females 
amenorrheic for at least 
12months)X
Urine drug testing X X
Supine 12 -Lead ECGjX X X X Xt
Blood pressure and pulse 
ratekX X X X Xt
Child- Pugh assessmentlX

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 10Visit IdentifieraScreeningbStudy Period Follow Ups
or Early 
TerminationtDays Relative to Day 1 Day -28 to 
Day -2Day -1 Day 1 Day 
2Day 
3Day 
4Day 
5Day 
6Day 
7Day 
8Day 
9Day 
10Day 
12
Hours After Dose 0246812 24 48 72 96 120 144 168 192 216 264
Hepatitis B (HepBsAg, 
HepBcAb),
Hepatitis C (HCVAb), and 
HIV testsX
Study treatment 
administrationmX
PKblood samplingnX X X X X X X X X X X X X X X X
Protein binding blood 
samplingoX X X
Pharm acogenomics blood 
sampling (CYP2D6)pX
Pfizer Prep D1 banked 
sample(s)qX
Prior/concomitant treatments X X                 Xs,t
CRU dischargerX
Serious and nonserious 
adverse event monitoringX X                 Xs,t
Abbreviations: = ongoing/continuous event; AE = adverse event; BMI = body mass index; CRU = clinical research unit; CYP = cytochrome P450 ; 
ECG =electrocardiogram; FSH =follicle -stimulating hormone; HCVAb = hepatitis C antibody; HepBcAb =hepatitis B core antibody; HepBsAg = hep atitis B 
surface antigen; HIV = human immunodeficiency virus ; PK = pharmacokinetic .
a.Day relative to start of stu dy treatm ent (Day 1).
b.Screening will be performed within 28 days prior to the dos ingof investigational product (dacomitinib) (Section 4.1).
c.All participant s will be admitted to the CRU on Day -1. All participant s will be required to stay in -house at least until the collection of the 144hour PK 
sample following dacom itinib dosing.
d.Dem ographics will include participant height, weight, race, age and gender data collected during Screening.
e.Medic al/medication history will include a history of illegal drug, alcohol, and tobacco use, as w ell as blood donation w ithin 60 days prior to first dose.  
Medical/medication history will be recorded at Screening and updated when the participant is admitted to the CRU on Day -1.
f.A complete physical exam ination may be conducted by a physician, trained physician's assistant, or nurse practitioner as acceptable according to local 
regulation at the investigator site either during Screening or Day -1 only (height and body  weight must be obtained at Screening to obtain BMI for eligibility 
criteria).  If complete physica l exam ination is performed during the screening visit, then only a brief physical exam ination is needed on Day -1.  A brief
physical exam ination maybe conducted at the discretion of the investigator on Day 7prior to discharge for new or ongoing AEs and during early 
termination .

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 11g.Safety laboratory assessments including urinalysis, hematology (including prothrombin time/partial thromboplastin time) , and chemistry will be performed 
at Screening, on Day -1, on Day 2, Day 7prior to discharge and during early termination.  All assessments must be collected follow ing at least a 4 -hour fast.  
For participant s with severe hepatic impairment ( Cohort 1), the Day -1safety labs including liver function assessments and evaluation of renal function must 
be completed prior to dacomitinib dosing on Day 1, for review  of inclusion/exclusion criteria.  Additional assessments may be performed at the discretion of 
the investi gator. 
h.On Day -1, on Day 7(or any subsequent day that coincides with discharge) and during follow -up or early termination, the investigator or his/her designee 
will discuss with the participant the need to use highly effective contraception consistently and correctly according to protocol contraception guidelines in
Section 5.3.4 .
i.Alcohol/tobacco use and alcohol breath test willbe performed during Screening or on Day -1.  The se tests may also be performed at any other time at the 
discretion of the investigator.
j.A single 12 -lead ECG will be obtained at Screening, 6 hours post -dose on Day 1, prior to discharge on Day 7and during early termination .  A triplicate ECG 
will be obta
ined approximately 2 to 4 minutes apart at pre -dose on Day 1. All ECG assessments will be made following at least a 10 -minute rest in a supine 
position and should be collected before PK sample collection, if scheduled at the same time point.
k.Supine blood pressu re will be determined following approximately 5-minute rest in a supine position. 
l.The modified Child -Pugh assessment as outlined inAppendix 8 should be follow ed. 
m.On Day 1,administration of dacomitinib will occur w ith approximately 8oz (240 mL) of ambient temperature water after at least a 10 hour fast. Following 
dacomitinib administration, no food w ill be allow ed for at least another 4hours post dose except that a light snack or juice may b e provided to a diabet ic 
participant .
n.Blood samples (3 mLeach)for PK will be taken upon completion of ECGs, blood pressure and pulse measurements.  Serial blood samples for the 
measurements of dacomitinib and its metabolite, PF -05199265, w ill be collected prior to dosing and at 2, 4, 6, 8, 12, 24, 48, 72, 96, 120, 144, 168, 192, 216 
and 264 hours following dosing.
o.Blood samples (10 mLeach) will be collected prior to dacomitinib dosing and at 6 and 8 hours following dosing.
p.One (1)blood sample ( 3mL) only will be collected o n Day -1 for CYP2D6 genotyping.
q.One (1)4mL blood sample should be drawn on Day -1.  If not collected on the designated collection day, collect at the next available time point when 
biospecimens are being collected in conjunction with a participant visit .
r.Participant s will be eligible for discharge from the CRU follow ing completion of the following : 144-hour PK sample collection, a single supine 12 -lead 
ECG, supine blood pressure and pulse rate, discuss ion of the need for highly effective contraception, sa fety lab oratory test, evaluation of participant -reported 
adverse events, revie w of prior and concomitant medications, brief physical examination, and body weight .Day 7safety lab oratory test s can be collected 
early (ie. On Day 6) so results are available in time for intended participant discharge on that day.
s.All participant s will be followed up by phone call at least 28 days and up to 35 days after the administration of the dacomitinib dose for potential AEs, 
concomitant treatment use and to confirm appr opriate contraception usage.
t.Participant withdrawal/ early termination activities will include a brief physical examin ation (if there is a new or ongoing AE or a previous clinically 
significant abnormal physical finding), safety laboratory tests, a contraception check, a single supine 12 -lead ECG, supine blood pressure and pulse rate , 
concomitanttreatment and AEassessment.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 122.INTRODUCTION
Dacomitinib (PF -00299804) is a selective, adenosine triphosphate (ATP) competitive, 
irreversible, small -molecule inhibit or of the HER (ERBB) family  of receptor ty rosine kinases 
(RTKs), including the epidermal growth factor receptor (EGFR, HER1), the HER2 receptor 
(ERBB2), the HER4 receptor (ERBB4), and their oncogenic variants (eg, EGFR with del 
exon 19 or L 858R mutations).
  It is currentl y approved for the first - line treatment of patients 
with locally  advanced or metastatic non -small cell lung cancer (NSCL C) with 
EGFR -activating mutations.
2.1.Study Rationale
The primary  metabolic pathway s for dacomitinib in human liver microso mes and human 
hepatocy tes in vitro are comprised of oxidation and glutathione conjugation.  I n vitro studies 
with human liver microsomes and recombinant cytochrome P450 ( CYP )(rCYP) enzy mes 
indicate dthat the formation of PF -05199265 (O -desmethy l dacomitin ib) was mediated 
primarily  by CYP2D6, while CYP3A was involved in the formation of other minor oxidative 
metabolites observed in humans following oral administration of a single dose of 
[14C]dacomitinib .
In the absorption, distribution, metabolism, and ex cretion (ADME) study in humans 
(Study A7471020), following oral administration of a single [14C]dacomitinib dose (45 mg, 
100Ci) to 6 male healthy  participant s, approximately  79% of the administered radioactive 
dose was recovered in feces 
(approximately 20% unchanged dacomitinib) and 3% in urine
(<1% unchanged dacomitinib) . 
Dacomitinib is orally  bioavailable with mean absolute 
bioavailability  of 80%.  These data indicate dsignificant hepatic component in the 
elimination of dacomitinib andminimal renal ex cretion of dacomintib .
A dedicated hepatic impairment clinical study  of dacomitinib (Study A7471018) in 
participant s with m ild or moderate hepatic impair ment has been completed .
Study A7471018 was a multi -center, Phase 1, open -label, non -randomized, singl e-dose, 
parallel group stud y conducted to evaluate the impact of mild hepatic impairment 
(Child -Pugh ClassA) or moderate hepatic impairment (Child -Pugh ClassB) on the 
pharmacokinetics (PK) of dacomitinib.  I n that study , a total of 25 men who had normal 
hepatic function ( n = 8), mild hepatic impairment (n = 8), or moderate hepatic impairment 
(n = 9) but were otherwise healthy  were enrolled and received a single 30 mg dose of 
dacomitinib following an overnight fasting for at least 8 hours.  Results demonst rated that 
plasma dacomitinib area under the concentration time curve from time 0 to infinity (AUC inf)
and maximum observed plasma concentration (Cmax)were similar in participant s with mild 
hepatic impairment and were reduced marginall y (by 15% and 20% for AUC infand Cmax, 
respectivel y)for participants w ith moderate hepatic impairment relative to participant s with 
normal hepatic function . 

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 13The effect of hepatic impairment on dacomitinib was further evaluated using the National 
Cancer Institute ( NCI)hepat ic impairment classification in a pooled population PKanaly sis 
of 1381 participant s, which included 158 participants with mild hepa tic impairment (total 
bilirubinupper limit of normal [ULN]and aspartate transaminase [ AST ] >ULN, or total 
bilirubin > 1 to 1.5 × ULN with any  AST), 5participant s with moderate hepatic impairment 
(total bilirubin >1.5 to 3 ×ULN and an y AST) and 1 participant with severe hepatic 
impairment (total bilirubin >
3 ×ULN and an y AS T). Limited data (n=1) w ereavailable for 
sever e hepatic impairment. Participant s with mild hepatic impairment had similar 
dacomitinib clearance ( CL) compared to participant s with normal hepatic function.  
Dacomitinib CL was higher in participant s with moderate hepatic impairment with me an CL
of 31.4 L/h (n=5 ) compared to 20.5 L/h (n= 1202) in participants with normal hepatic 
function. Hepatic function was not a significant covariate on dacomitinib CL . 
Based on the results from both the formal hepatic impairment Study A7471018 and the 
pooled 
population PK analy sis, mild ormoderate hepatic impairment isconsidered to not
have aclinically  relevant effect on dacomitinib PK. Therefore, no dose adjustment of 
dacomitinib is recommended in patients with mild or moderate hepatic impairment. 
Insufficient da ta are however available regarding the use of dacomitinib in patients with 
severe hepatic impairment to provide dosing recommendations in this patient population.
The purpose of th isstudy is to evaluate the effect of severe hepatic impairment on the single 
dose PKof dacominitinib.
2.2.Background 
2.2.1. Nonclinical Pharmacology
Dacomitinib is a highl y selective irreversible small molecule inhibitor of the HER (human 
epidermal growth factor receptor) family  of tyrosine kinases.  The IC50values against the 
human cata lytic domains of HER -1, HER -2, and HER -4 (HER -3 does not possess ty rosine 
kinase activity ) are 2.8 ng/mL (6.0 nM), 21.5 ng/mL  (45.7 nM) and 34.7 ng/mL (74 nM), 
respectivel y.  Dacomitinib is >500 selective relative to the concentrations required to 
inhibi t the janus kinase 3 (JAK3 ), protein kinase b ( Akt) , insulin -like growth factor 
1receptor (IGF1R), and the 
platelet -derived growth factor receptor (PDGFR )in kinase 
assay s.  The IC 50values are 1676, >18,800, >18,800, and 6298 ng/mL (3566, >40,000, 
>40,000, and 13,400 nM), respectivel y.  Dacomitinib inhibits the ty rosine kinase activity  of 
the HER family  through binding at the ATP binding site, which results in covalent 
modification of a cy steine in the ATP binding pocket.  Dacomitinib exhibited anti -tumor
effects in 4 different human xenograft models that express and/or overexpress HER family 
members.  In these xenograft models, the therapeutic activity  ranged from complete 
regression to delay ed progression.  The inhibitory  effects on tumor growth generall y lasted 
throughout compound administration.  An active metabolite, PF-05199265, has been 
identified which has similar inhibitory and selectivity  profile scompared to dacomitinib . 

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 142.2.2. Nonclinical Pharmacokinetics and Metabolism
In nonclinical species (rats, d ogs, and monkey s), dacomitinib exhibited moderate to high 
total plasma clearance in relation to hepatic blood flow , high volume of distribution, and 
moderate to high oral bioavailability  ranging from 56% to 109%. Ratios of the AUC from 
time 0 to 24 hours post dose (AUC 24) for PF -05199265, a circulating active metabolite in 
humans, to parent were 0.18 in rats and 1.9 in dogs after oral administration of dacomitinib 
for 3 days.  In toxicokinetic studies with rats, rabbits, and dogs, sy stemic exposure of 
dacom itinib generall y increased with increasing of dose within the dose ranges examined.
After oral administration, [14C]dacomitinib undergoes oxidation and glutathione conjugation 
as the primary  metabolic pathway s in rats, dogs, and humans.  Formation of PF -05199265 is 
mediated primaril y by CYP2D6 and to a lesser extent, by CYP2C9.  CYP3A4 contributes to 
the metabolism of dacomitinib in the formation of other minor oxidative metabolites. The 
route of excretion of radioactivity  in rats, dogs, and humans was pri maril y via feces. 
Dacomitinib and PF-05199265 demonstrated little or no inhibition of CYP1A2, CYP2B6, 
CYP2C8, CYP2C9, CYP2C19, or CYP3A activities in human liver microsomes.  However, 
dacomitinib and PF -05199265 inhibited CYP2D6 activity , and may  have the potential for 
clinically  relevant drug -drug interaction (DDI) with concomitantly  administered CYP2D6 
substrates.  No significant induction of CYP3A, CYP1A2 or CYP2B6 in cryopreserved 
human hepatocy tes was observed.  Based on in vitro data, dacomitinib may have the potential 
to inhibit uridine -diphosphate glucuronos yltransferase (UGT)1A1 activity .
Dacomitinib has a low potential to cause DDI by  inhibiting the efflux transporters 
P-glycoprotein (P -gp) s ystemically, organic anion transporting pol ypeptides (OA TP)1B1, 
OATP1B3, organic anion transporter (OAT)1, OAT3, organic cation transporter (OCT)2, and 
human bile salt export pump (BSEP). However, dacomitinib may  have the potential to 
inhibit breast cancer resistance protein (BCRP), P- gp in the gastrointestina l (GI) tract, and 
OCT1.
2.2.3. Nonclinical Safety
Dacomitinib was assessed in a series of nonclinical studies that included repeated -dose 
toxicity  studies in rats and dogs up to 6 or 9 months in duration, respectively , and safet y 
pharmacology , genotoxicity , and r eproductive embry o-fetal development studies.  Based on 
the nonclinical studies conducted, the kidney , digestive sy stem, epithelial cells, and liver 
have been identified as the primary  target tissues/organs of toxicity .  Based on the results of 
the genotox icity assay s conducted, dacomitinib would not be expected to pose a genetic risk 
for acute or chronic dosing in humans.  Embry o-fetal development studies were performed in 
rats and rabbits where the effects were limited to reductions in maternal and fetal body  
weight, and lower maternal food consumption.  There was no teratogenicity, mortality , or 
moribundity
 detected at any  dose level tested.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 152.2.4. Clinical Overview
As of 29 July  2016, 3182 patients have been treated in 17 clinical studies and 143 healthy  
participant s and 15 patients with solid tumors have been treated in 9 clinical pharmacology  
studies.  Dacomitinib was administered to 2148 of the patients in these trials, in 1975 patients 
as a single agent or in combination with figitumumab (CP -751,871, a mono clonal antibody  
targeting the IGF1R ), crizotinib ( an anaplastic lymphoma kinase [ ALK
],
mesench ymal-epithelial transition [MET] and c -ROS oncogene 1 [ROS1] tyrosine kinase 
inhibitor), or gedatolisib (PF-05212384, a phosphoinositide 3 -kinase [PI3K]/mTOR 
inhibitor), and in 173 patients in Phase 1 combination therap y studies.  Most p atients treated 
in clinical studies had locally  advanced or metastatic 
NSCL C.  There were 1473 patients with 
NSCL C who received single- agent dacomitinib 45 mg once dail y (QD), the m aximum 
tolerated dose as determined by  Studies A7471001, A7471003, and A7471005.  Of these 
patients, 394 patients had NSCL C with EGFR -activating mutations; 255 of these patients 
received dacomitinib as first- line treatment.
The most frequentl y reported adv erse events ( AEs)in 10% of patients include dGI-related, 
skin-and-nail-related, respiratory , and constitutional events.  
Results from Study A7471015 indicate d that dacomitinib can be administered with or 
without food.
  Following a single oral administra tion of dacomitinib at 45 mg in patients with 
advanced malignant solid tumors, the median time to reach the maximum observed plasma 
concentration (T max) of dacomitinib occur redapproximately  at 5 to 6 hours after dosing.  
Dacomitinib under went extensive ex travascular distribution with a geometric mean apparent 
volume of distribution (V z/F) ranging from 2424 to 2537 L/h and ha d a mean appare nt 
terminal plasma half -life (t ½) ranging from 54 to 80 hours.  Following administration of 
multiple daily  doses of dac omitinib at 45 mg to patients with advanced malignant solid 
tumors, steady -state wa s reached within 14 days,accumulation of dacomitinib in patients 
range dfrom 5. 0to 6.4-fold for AUC, reflecting the observed long t ½.The geometric AUC
over dosing interv al (AUC tau) and Cmaxof dacomitinib at steady -state range dfrom 1
621to 
2213 ng•h/mL and 7 9.5to 10 8.0ng/mL, respectively .Plasma exposure of dacomitinib 
increase dproportionall y with dose in the dose range of 2 mg to 60 mg, indicating linear PK.
Dacomi tinib undergoes oxidative metabolism and glutathione conjugation.  Oxidative 
metabolism of dacomitinib involves CYP2D6 for the formation of O -desmethy l dacomitinib 
(PF-05199265) and CYP3A for the formation of other minor oxidative metabolites. The 
O-desme thyl metabolite, PF -05199265, is also a potent inhibitor of the HER kinase family  in 
vitro.  However, the steady -state exposure of PF -05199265 in human plasma is <20% when 
compared with the exposure observed for dacomitinib.  Furthermore, PF -05199265 is al so 
highl y bound to plasma proteins (>99%), which indicates that the unbound fraction for 
PF-05199265 in plasma is <1% of the reported total plasma exposure .
A dedicated hepatic impairment study  (Study  A7471018 ) was conducted to evaluate the 
effect of hepa tic impairment on dacomit inib exposure after a single 30 mg dose.  This was a 
Phase 1 open- label, non -randomized, single -dose, parallel -group stud y in 25participant s with 
mild hepatic impairment (Child -Pugh Class A , score 5-6, n = 8), moderate hepatic 

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 16impairment (Child- Pugh ClassB, score 7-9, n = 9), and a control group of healthy  
participants with normal hepatic function (n= 8).  The results showed that t he mean fraction 
of dacomitinib unbound in plasma (f u) was identical across the 3 groups ( fu= 0.02) .  The 
mean ( percent coefficient of variation [%CV]) f uof PF-05199265 was 0.00011 (28 %), 
0.00016 (69%), and 0.00025 (62% ) for participant s with normal hepatic function, mild 
hepatic impairment, and moderate hepatic impairment, respectivel y.  Results also showed 
that mild hepatic impairment status did not alter dacomitinib plasma exposures and that 
moderate hepatic impairment status reduced dacomitinib plasma exposures (AUC infand C max
by 15% and 20%, respectively ) as compared to normal hepatic function. T hese changes are 
not considered clinically  significant and no starting -dose adjustment is currently  
recommended for patients with mild or moderate hepatic impairment. In addition, a single 
oral 30mg dose of dacomitinib was well tolerated in participants with mild ormoderate 
impaired hepatic function.  No participant s in the normal hepatic function group or the mild 
hepatic impairment group experienced an AE.  One (1) participant in the moderate hepatic 
impairment group died due to a road traffic accident . This death was classified as a serious 
adverse event (SAE )and was considered to be severe but was not treatment -related.  There 
were no laboratory  safet y tests, vital signs results, or electrocardiogram ( ECG )results of 
clinical concern.
2.3.Benefit/Risk A ssessment
Dacomitinib is not expected to provide an y clinical benefit to theparticipants of this study .  
This study  is designed to evaluate safet y, tolerability , and PK in participant s with severe 
hepatic impairment and matched controls to assist thefurther clinical development of 
dacomitinib .
More detailed information about the known and expected benefits and risks and reasonabl y 
expected AEs of dacomitinib may be found in the investigator’s brochure (IB), which is the 
single reference safet y document (S RSD) for this study . 

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 173.OBJECTIVES AND ENDPO INTS
Objectives Endpoints
Primary : Primary : 
To evaluate the effect of severe hepatic 
impairment on the single dose plasma
PK of dacomitinib.Plasma C maxand AUC infof dacomitinib. 
If AUC infcannot be reliably  estimated ,
then AUC from time 0 to the time of last 
quantifiable concentration ( AUC last)will 
be used as the primary  endpoint.
Secondary : Secondary : 
To assess the safet y and tolerability of a 
single oral dose of dacomitinib in 
participant s with normal hepatic 
function and participant s with severe 
hepatic impairment.Overall safet y profile as characterized b y 
laboratory  test abnormalities, phy sical 
examination, vital signs, ECGs, and AE
monitoring.
Tertiary /Exploratory : Tertiary /Exploratory : 
To chara cterize the effect of severe 
hepatic impairment on other plasma PK
parameters of dacomitinib and its 
metabolite PF -05199265.Plasma AUC last, apparent oral clearance 
(CL/F), V z/F, t ½, Tmax, fu, unbound 
AUC inf(AUC inf,u), unbound AUC last
(AUC last,u), unbound Cmax (Cmax,u), 
unbound CL /F (CL u/F) and unbound V z/F 
(Vz,u/F) fordacomitinib; C max, AUC inf, 
AUC last, t½, Tmax, fu, AUC inf,u, AUC last,u, 
Cmax,u forPF-
05199265, as data permit .
To anal yze CYP 2D6 genoty pe in 
pharmacogenetic samples. CYP2D6 phenoty pe.
Toenable exploratory  research through 
collection of banked biospecimen s, 
unless prohibited by local regulations or 
ethics committee decision.Potential results from exploratory  
analysis of banked biospecimen s(these 
results may  or may  not be generated in 
the context of the present study ).
4.STUDY DESIGN
4.1.Overall Design
This will be a Phase 1, open- label, parallel -group study  to investigate the effect of severe 
hepatic impairment on the plasma PK, safety  and tolerability after a single oral 30 mg dose of 
dacomi tinib under fasted conditions. 

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 18At Screening, the modified Child -Pugh classification score asoutlined in Appendix 8 will be 
utilized to assess entry  criteria and to assign participant s into the appropriate hepatic 
impairmen t group ( Table 1). The modified Child -Pugh classification criteria will permit 
enrollment of participant s with 
a history  of Stage 3 or S tage 4 encephalopathy  who are 
receiving medication(s) to prevent recurrent encephalopathy ; participant s with clinically  
active 
Stage 3 or 4 encephalopathy  will be excluded from participation in the study .The 
criteria will also allow enrollment of participant s with history  of severe ascites who are on 
medication(s) to control their ascites. Deta ils of the modified Child- Pugh asses sment can be 
found in Appendix 8.
Table 1. Hepatic Function Categories Based on Child -Pugh Classification
Cohort Description Child -Pugh Score Number of 
Participant s
1 Severe h epatic impairment Class C (10 to 15 points) 8
2 Normal hepatic function Not applicable 8a
a.Participant s in Cohort 2may be dosed to a maximum of 10 participant s to ensure that theageof each 
participant in C ohort 2 is within 10years and the body  weight is within 15kg to the median age and 
median body  weight of participants in Cohort 1, respectively .
Approximately 18participants will be enrolle d into the study  to ensure at least 6 PK 
evaluable (having data for estimating primary  PK param eters for dacomitinib )participant s in 
each cohort .  Participant s who withdraw may  be replaced upon agreement with the Sponsor .
The participant s from the severel y impaired hepatic function cohort will be recruited first, 
and a median value for age and weig ht will be determined for all evaluable participant s 
across stud y sites in this cohort. Then the control
participant s from the normal hepatic 
function cohort will be recruited later such that the age of each participant in C ohort 2 is 
within10years and the body  weight is within 15kg of the median of the participants in 
the severe hepatic impairment cohort (Cohort 1 ).  An attempt will be made to maintain a 
similar male/female ratio and racial make -up between Cohorts 1 and 2. Approval from the 
Sponsor must be obtained before proceeding with dosing participant s in Cohort 2. 
In this stud y, participant s will be screened for participation within 2 8days prior to the dosing 
of dacomitinib .  Each 
participant will be admitted to the clinical research unit (CR U) on 
Day -1.  Results from the Day - 1 safet y assessments will be reviewed along with the 
screening assessments and the participant ’s recent medical history toensure that each 
participant meets the inclusion and exclusion criteria for this study  as define d in Sections 5.1
and 5.2of this protocol, respectivel y.  Additional assessment may  be done at the discretion of 
the investigat or. Participant s who meet the inclusion and exclusion criteria for the study  on 
Day -1will be assigned a randomizati on number on Day 1 (see Section 6.3 fordetails), and 
will be enrolled into the study .

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 19Following an overnight fast of at least 10 hours, participant s will be administered a single 
oral 30mg dose of dacomitinib with approximately  240 mL (8ounces) of ambient 
temperature water on the morning of Day 1.  No food will be allowed for at least 4 hours 
post-dose except that a light snac k or juice may  be provided to diabetic participants .  Each 
participant will undergo serial blood sampling to determine plasma concentrations of 
dacomitinib and PF- 05199265 until 264hours (Day 12) post-dose.  At pre -dose and at 6and 
8hours post -dose, separate aliquots of blood ( 10mL) willbe collected for measurement of
protein binding.  Participant s will be confined to the unit until D ay7.
After the PK data from all participant s with severe hepatic im pairment (Cohort 1) have been 
reviewed, the Sponsor will notify  the site if additional 
participant sfor Cohort 1are required.  
If no additional participant s are required, recruitment for participant s with normal hepatic 
function (Cohort 2) will begin.  I fthe PK variability  is greater than expected, additional 
participant s may  be enrolled in Cohort 1 and the sample size for Cohort 2 will also be 
increased accordingl y. 
Physical examinations, single or triplicate supine 12 -lead ECG , vital sign measurements, and 
clinical laboratory  tests will be conducted and AEs will be monitored throughout the stud y to 
assess safet y.  All participants will be followed up by  a phone call at least 28days and up to 
35days after dacomitinib dosing . 
4.2.Scientific Rationale for Study Design
A parallel group design will be utilized to compare the dacomitinib PK between participant s 
with normal hepatic function and participant s with severel y impaired hepatic function but are 
otherwise healthy .The participant s from the severely  impaired hepatic function cohort will 
be recruited first, then the participant s from the normal hepatic function cohort will be 
recruited later to match the median demographics from severe hepatic impairment group. 
The modified Child -Pugh classification s ystem will be the method used in this study  to 
identify  participant s with severe hepatic impairment. Additionally , total bilirubin and AST 
will be assessed in this study  as per the recommendations of the National Cancer Institute 
Organ Dy sfunction Working Gr oup Criteria for assessment of hepatic impairment.2
This study  is designed using a single dose of dacomitinib considering that sin gle dose plasma 
PK of 
dacomitinib has been documented to be generall y predictiv e of exposure at stead y
state.All participant senrolled in this study  will receive 1single oral 30mg dose of 
dacomitinib administered as tablet(s) .  The PK samples will be collected serially  up to 
264hours post
dose, which has been shown to be adequate for participant s with normal , mild 
ormoderate hepatic function.   This sampling duration is also expected to be adequate for 
characterizing the elimination phase of the plasma dacomitinib concentration -time profile for 
participant s with severe hepatic imp airment ,for whom the elimination half -life of 
dacomitinib may  be prolonged.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 20Dacomitinib undergoes both oxidative metabolism and glutathione conjugation.  Oxidative 
metabolism of dacomitinib involves CYP2D6 for the formation of major circulating 
metabolite ,PF-05199265, which has similar in vitro pharmacological activities as 
dacomitinib. Therefor ethe plasma PK for both dacomitinib and PF -05199265 will be 
evaluated 
in this study .
Since CYP2D6 metabolism is a component of dacomitinib elimination, genetic 
polymorphisms of CYP2D6 may  have the potential to alter dacomitinib PK.  A 3 -mL blood 
sample will be collected on Day  -1from each participant for genot yping CYP2D6 
polymorphism. Only participants identified as an CYP2D6 extensive metabolizer ( EM) or
CYP2D 6 intermediate metabolizer (IM) will be included in the primary  statistical analy sis to 
evaluate the impact of severe hepatic impairment on dacomitinib plasma PK .
Banked biospecimens will be collected for exploratory  pharmacogenomics (PGx) /genomic 
analyses and retained in the Biospecimen Banking Sy stem (BBS), which makes it possible to 
better understand the investigational product’s (IP’s) mechanism of action and to seek 
explanations for differences in, for example, exposure, tolerability , safet y, and/or efficacy  not 
anticipated prior to the beginning of the stud y.
4.3.Justification for Dose
Inthe current study , a single 30 mg oral dose of dacomitinib will be administered to 
participants with normal hepatic function orparticipant
s with severe hepatic impairment.  
The single oral dose of dacomitinib 30 mg is the same dose that was tested in the previously  
conducted hepatic impairment study  of dacomitinib (Study A7471018), where this dose was 
well-tolerated in participants with mild or moderate hepatic impairme nt.  There were no 
clinically  significant findings in vital signs, clinical laboratory  test parameters, or ECGs.
Hence p revious investigation
s have indicated that mild and moderate hepatic impairment had 
no clinically  relevant effects on dacomitinib PK ,and no adjustment of starting dose is 
currentl y recommended for patients with mild or moderate hepatic impairment. In addition, 
there were 1473 patients with advanced NSCL C who received dacomitinib 45 mg QD, the 
recommended 
starting dose. Following multiple oral administration of 45 mg QD dose s, 
accumulation of dacomitinib in patients rang edfrom 5.0 -to 6.4 -fold for AUC tau. The AUC 
in participant s receiving a single 30 mg dose is expected to be 7.5 to 9.6 fold lower than the 
exposure in 
patients receiving 45 mg QD at stead y state . 
4.4.End of Study Definition
A participant is considered to have completed the study  if he/she has completed all phases of 
the study  including the last scheduled procedure shown in the SoA.
The end of the stud y is defined as the date of the last visit of the last participant in the study .

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 215.STUDY POPULATION
This study  can fulfill its objectives only  if appropriate participant s are enrolled.  The 
following eligibility  criteria are designed to select participant s for whom participation in the 
study  is considered appropriate.  All relevant medical and nonmedical conditions should be 
taken into consideration when deciding whether a particular participant is suitable for this 
protocol .
Prospective approval of protocol deviations to recruitment and enrollment criteria ,also 
known as protocol waivers or exemptions, is not permitted .
5.1.
Inclusion Criteria
Participants are eligible to be included in the study onl y if all of the following criteria appl y:
5.1.1. All Participants
Age and Sex :
1.Male and/or female p articipant sof non-childbearing potential must be 18 to 75years 
of age ,
inclusive, at the time of signing the informed consent document (ICD) .
Refer to Appendix 4for reprod uctive criteria for male ( Section 10.4.1 ) and female 
(Section 10.4.2) participants.
Type of Participant and Disease Characterist ics:
2.Participants who are willing and able to compl y with all scheduled visits, treatment 
plan, laboratory  tests
, lifesty le considerations, and other study  procedures.
Weight:
3.Body mass index (BMI) of 17.5 to 40kg/m2; and a total body  weight >50 kg (110 lb).
Informed Consent:
4. Capable of giving signed informed consent as described in Appendix 1 ,which 
includes compliance with the requirements and restrictions listed in the I CDand in 
this protocol.
5.1.2. Additional I nclusion Crite ria for Pa rticipant s with Normal Hepatic Function 
(Cohort 2)
1.
No known or suspected hepatic impairment based on l iver function tests (eg, alanine 
aminotransferase [ALT], AST, alkaline phosphatase [AL P], and bilirubin) , albumin 
and prothrombin time defined a s the following, with a single repeat permitted to 
assess eligibility , if needed:
a.ALT and AST upper limit of normal (ULN);

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 22b.Total bilirubin ULN. Note that participant s with a history  of Gilbert s yndrome 
(and hence elevated total bilirubin) are eligible pr ovided direct bilirubin level is 
ULNplus ALT and AST are  ULN plus alkaline phosphatase, hemoglobin, and
reticulocy te count are all ULN;
c.ALPULN;
d.Albumin within the normal range (local laboratory ranges) ;
e.Prothrombin time ULN.
2.Healthy is defined as no clinically  relevant abnormalities identified by  a detailed 
medical history , complete physical examination, including blood pressure (BP) and 
pulse rate measurement, 12
-lead ECG or clinical laboratory  tests.
3.Participant s mu stfit the demographic -matching c riteria , including :
Body weight  15kg of the median of the severe hep atic impairment cohort 
(Cohort 1), as provided by  the Sponsor .
Age 10years of the median of the severe hep atic impairment cohort (Cohort 1), 
as provided b y the Sponsor .
5.1.3. Additional Inc lusion Criteria for 
Participant s with Severely Impaired Hepatic 
Function (Cohort 1)
1.Satisfy  the criteria fo r Class C (severe hepatic impairment) of the modified 
Child -Pugh classification. 
2.A diagnosis of hepatic dysfunction due to hepatocellular disease (a nd not secondary  
to any  acute ongoing hepatocellular process) documented by  medical history , 
physical examination, liver biopsy , hepatic ultrasoun d, computerized tomograph y 
scan, or magnetic resonance imaging (MRI).
3.Stable hepatic impairment, defined as no clinically significant known change in 
disease status within the last 30 days, as documented by  the participant ’s recent 
medical history  (eg, no worsening clinical signs of hepatic impairment, or no 
worsening of total bilirubin or prothrombin time by more than 50%). 
4.Stable drug regimen is defined as not starting a new drug or changing dosage within 
7days or 5half-lives (whichever is longer) prior to the dosing of dacomitinib . 
5.History  of alcohol abuse is permissible providing that the results of alcohol test are 
negative at Screening or on Day  -1, and the participant is willing and able to abide b y 
the lifesty le guidelines described in 
Section 5.3.2 of this protocol.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 235.2. Exclusion Criteria
Parti cipants are excluded from the study  if any  of the following criteria apply :
5.2.1. All Participants
Medical Conditions:
1.Any condition possibly  affecting drug absorption (eg, gastrectomy ).
2.Other acute or chronic medical or ps ychiatric condition including recent ( within the 
past y ear) or active suicidal ideation or behavior or laboratory  abnormality  that may  
increase the risk associated with study participation or IPadministration or may  
interfere with the interpretation of study results and, in the judgment of th e 
investigator, would make the participant inappropriate for entry  into this study .
3.History  of or current positive results for human immunodeficiency  virus (HIV).
Prior/Concomitant Therapy:
Not applicable.
Prior/Concu rrent Clinical Study Experience :
4.Previous administration with an investigational drug within 30 days (or as determined 
by the local requirement) or 5 half-lives preceding the first dose of IPused in this 
study  (whichever is longer). 
5.Hypersensitivity  to dacomitinib or its excipients.
Diagnosti c Assessments:
6.A positive urine drug test .Participant s with severe hepatic impairment (Cohort 1) 
will be eligible to participate if their urine drug test is positive with a drug for a 
prescribed condition that is not expected to interfere with the PK of dacomitinib.
Other Exclusions:
7.Blood donation (excluding plasma donations) of approximately  1pint (500 mL)or 
more within 60days prior to dosing .
8.History  of sensitivity  to heparin or heparin -induced thrombocy topenia .
9.Unwilling or unable to comply  with t he criteria in the Lifesty le Considerations
section of this protocol
.
10.Investigator site staff members directl y involved in the conduct of the study and their 
family  members, site staff members otherwise supervised by the investigator, or 
Pfizer employ ees, including their family  members, directly  involved in the conduct of 
the study .

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 245.2.2. Additional Exclusion Criteria for Participant s with N ormal Hepatic Function 
(Cohort 2 )
In addition, participant s in the normal hepatic function cohort (Cohort 2) presenting with any  
of the following will not be included in the study :
1.Evidence or history  of clinically  significant hematological, renal, endocrine, 
pulmonary , gastrointestinal, cardiovascular, hepatic, psy
chiatric, neurologic , or 
allergic disease (including drug allergies deemed relevant for participation in this 
study , but excluding untreated, as ymptomatic, seasonal allergies at the time of 
dosing).
2.History  of regular alcohol consumption exceeding 7 drinks/week for females or
14 drinks/week for males (1 drink = 5 ounces (150 mL) of wine or 12 ounces 
(360 mL) of beer or 1.5 ounces (45 mL) of hard liquor) within 6 months of Screening.
3.Screening supine BP140mm Hg (s ystolic) or 90mm Hg (diastolic), following at 
least 5 minute s of supine rest.  If initial supine BP is 140mm Hg (s ystolic) or 
90mm Hg (diastolic), the BP should be repeated 2more ti mes and the average of 
the 3 BP values should be used to determine the participant ’s eligibility . 
4.Screening 12- lead ECG demonstra ting corrected QT (Fridericia method) 
(QTcF)>450 msec and/or a QRS complex >120 msec.   If initial QTcF exceeds 
450msec, or QRS complex exceeds 120 msec , the ECG should be repeated 2 more 
times and the average of the three QTcF and/or QRS complex values s hould be used 
to determine the participant ’s eligibility .
5.Use of prescription or nonprescription drugs and dietary  supplements within 7 days or 
5half-lives (whichever is longer) prior to the first dose of study  medication .  As an 
exception, acetaminophen /paracetamol may  be used at doses of 1g/day .  Limited 
use of nonprescription medications that are not believed to affect participant safet y or 
the overall results of the study  may  be permitted on a case by  case basis following 
approval b y the Sponsor .  Herbal supplements and hormone replacement therap y 
must have been discontinued at least 28 days prior to the dose of 
dacomitinib .
6.Participant s with a history  of or current positive results for hepatitis B or hepatitis C, 
including hepatitis B surface antige n (HepBsAg), hepatitis B core antibod y 
(HepBcAb), or hepatitis C antibody  (HCVAb).
5.2.3. Additional Exclusion Criteria for Participants with Severely Impaired Hepatic 
Function (Cohort 1)
1.Other clinicall y significant disease that contraindicates stud y drug or tha t may  affect 
the PK of dacomitinib (stable, chronic, controlled disorders such as h ypertension and 
diabetes may  be acceptable upon S ponsor agreement ). 
2.Hepatic carcinoma and hepatorenal sy ndrome.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 253.Undergone porta -caval shunt surgery . 
NOTE: Participant s wit h a transjugular intrahepatic portosy stemic shunt (TIPS) are 
permitted provided that th ey meet the Child -Pugh classification criteria.
4.History  of gastrointestinal hemorrhage due to esophageal varices or peptic ulcers less 
than 1 month prior to study  entry .
5.Any clinically  significant laboratory  abnormality  except for those parameters 
influenced b y hepatic impairment. 
6.Participant s with an estimated glomerular filtration rate (eGFR) of 
60mL/min/1.73 m2based on the Modification of Diet in Renal Disease (MD RD) 
equation, with a single repeat permitted to assess eligibility , if needed; 
7.Presence of clinicall y active Stage 3 or 4 encephalopathy .
8.Severe uncontrolled ascites and/or pleural effusion.
9. S creening supine blood pressure 160mm Hg (s ystolic) or  90mm Hg (diastolic), on 
a single measurement following at least 5 minutes of rest.  If initial supine BPis 
160mmHg (s ystolic) or 90mmHg (diastolic), the BP should be repeated two 
more times and the average of the three BP values should be used to determine the 
participant ’s eligibility .
10.Screening supine 
12-lead ECG demonstrating QTcF >4 70msec.  If initial QTcF 
exceeds 470 msec, the ECG should be repeated two more times an
d the average of the 
three QTcF values should be used to dete rmine the participant’ s eligibility .
11.Use of food, drugs, or dietary  supplements that may  affect the PK of dacomitinib
within 7 days or 5 half-lives (whichever is longer) prior to the dose of dacomitinib .  
Use of medications that are not believed to affect participants’ safet y and are 
medically  necessary  for the treatment and maintenance of hepatic disease and other 
pre-existing and/or concurrent sta ble comorbid conditions are permitted with
approval b y the Sponsor .  Limited use of nonprescription medications that are not 
believe d to affect participants ’safet y or the overall results of the study  may  be 
permitted on a case b y case b asis with approval b y the Sponsor .  Herbal supplements 
and hormone replacement therap y must have been discontinued at least 28 days prior 
to the dose o f dacomitinib .
12.Use of CYP2D6 substrates with a narrow therapeutic index.
13.Use of food or drugs that are CYP2D6 inhibitors within 7 days or 5 half-lives 
(whichever is longer) prior to the first dose of dacomitinib until the completion of the 
last PK sample c ollection.  All concomitant medication must be approved by the 
Sponsor .

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 2614.Use of proton- pump inhibitors (PPI s)within 7 days prior to the first dose of 
dacomitinib until the completion of the last PK sample collection. 
15.Participants will abstain from taking lactulose or other medications which could result 
in diarrhea or have excessive (>2) bowel movements per day  within 24hours prior to 
dacomitinib dosing and 24hours post dosing.
5.3.Lifestyle Considerations
The following guidelines are provided:
5.3.1. Meals and Die tary Restrictions
Participant s must abstain from all food and drink (except water) at least 4 hours prior 
to any  safety laboratory  evaluations and 10 hours prior to the collection of the predose 
PKsample on Day 1.
Water is permitted until 1 hour prior to 
dacomitinib administration on Day 1.  Water 
may be consumed without restriction beginning 1 hour after dosing.
  No food will be 
allowed for at least 4 hours postdose except that a light snack or juice may  be provide 
to a diabetic particpant .
Lunch will be provided approximately  4hours after dacomitinib dosing on Day 1.
Dinner will be provided approximately  9to 10 hours after dacomitinib dosing on 
Day 1.
An evening snack may be permitted .
Participants will refrain from consuming red wine, grapefruit, or grapefruit -related 
citrus fruits (eg, Seville oranges, pomelos, fruit juices) from 7 days prior to the first 
dose of IPuntil collection of the final PK blood sample. 
While participants are confined, the irtotal daily  nutritional composition should be 
approximately  55% carbohy drate, 30% fat,and 15% protein.  The dail y caloric intake 
per participant should not exceed approximately  3200 kcal.
5.3.2. Caffeine, Alcohol, and Tobacco
Participant s will abstain from alcohol for 24 hours prior to admission to the CRU and 
continue abstaining from alcohol until collection of the final PK sample.  Participant s 
will undergo an alcohol breath test as indicated in SoA.
Consumption of caffeinated drinks and nicotine containing products (5cigarettes per 
day or equivalent) is permitted during participation in the study ; however, participant s 
will abstain from nicotine or caffeine containing products for at least 2 hours prior to 
any scheduled 
ECG or BPdeterminations. 

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 275.3.3. Activity
Particip ants will abstain from strenuous exercise (eg, heav y lifting, weight training, 
calisthenics, aerobics) for at least 48 hours prior to each blood collection for clinical 
laboratory  tests.  Walking at a normal pace will be permitted.
In order to standardize the conditions on PKsampling day s, participant s will be 
required to refrain from ly ing down (except when required for BP, pulse rate , and 
ECG measurements), eating, and drinking beverages other than water during the first 
4hours after dacomitinib dosing .
5.3.4. Contraception
The investigator or his or her designee, in consultation with the participant , will confirm that 
the 
participant has selected an appropriate method of contraception for the individual 
participant and his or her partner(s) from the permitted list of contraception methods (see 
Appendix 4,Section 10.4.4 )and will confirm that the participant has been instructed in its 
consistent and correct use.  At time points indicated in the SoA, the investigator or designee 
will inform the participant of the need to use highly  effective contraception consistently  and 
correctly  and document the conversation and the participant ’s affirmation in the participant ’s 
chart ( participant s need to affirm their consistent and correct use of at least 1 of the selected 
methods of contraception).  In addition , the investigator or designee will instruct the 
participant to call immedia tely if the selected contraception method is discontinued or if 
pregnancy  is known or suspected in the 
participant or partner.
5.4.Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subseque ntly randomly  assigned to IP/entered in the study .  Screen f ailure data are 
collected and remain as source and are not reported to the clinical database.
Individuals who do not meet the criteria for participation in this study  (screen failure) may  be 
rescr eened. 
Addit
ionally  during Screening: 
For inclusion and Child -Pugh classification , clinical laboratories that are deemed 
inconsistent, by  the investigator, with the usual stage of hepatic impairment may  be 
repeated;
For eligibility  purposes, vital signs, laboratory tests, or ECG results may  be repeated 
if an abnormal result is observed at the initial reading;
In the event that the participation of a participant in the study  is delay ed and any  
required screening procedures will be outside of the allowed sc
reening window 
(28days), these screening procedures can be repeated;

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 28Participant s who are not qualif iedbased on a reversible medical condition or 
mild/acute/intercurrent illness may be re -evaluated after fu rther testing/examination 
or re-screened after t he condition has resolved.
6.STUDY INTERVENTION
Study  intervention is defined as any  investigational intervention(s), marketed product(s), 
placebo, or medical device(s) intended to be administered to a study  participant according to 
the study  protocol.
For t he purposes of this protocol, the term IPm
ay be used s ynon ymously with study  
intervention.
6.1.Study Intervention Administered
For this study , the IPis dacomitinib.
Tablets will be supplied to the CRU in bulk along with individual dosing containers for unit 
dosing.
6.1.1. Administration
Following an overnight fast of at least 10 hours, participant s will receive a single 30mg 
dacomitinib tablet at approximately  0800 hours (2hours).  Investigator site personnel will 
administer dacomitinib tablet with approximately  240 mL of ambient temperature water.  
Participant s will swallow the tablet whole, and should not manipulate or chew the tablet prior 
to swallowing.
6.2.Preparation/Handling/Storage/Accountability
1. The investigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study  intervention sreceived and an y 
discrepancies are reported and resolved before use of the study  intervention , as 
applicable for temperature -monitored shipments . 
2.Only  participants enrolled in t he study  may  receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention.   All study 
interventions must be stored in a secure, environmentally  controlled, and monitored 
(manual or automated recording) area in accor dance with the labeled storage 
conditions with access limited to the investigator and authorized site staff.  At a 
minimum, daily  minimum and maximum temperatures for all site storage locations 
must be documented and available upon request.  Data for nonwo rking days must 
indicate the minimum and maximum temperature since previousl y documented for all 
site storage locations upon return to business
.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 293.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stu dy intervention accountability , reconciliation, and record 
maintenance (ie, receipt, reconciliation, and final disposition records). All study  
intervention swill be accounted for using a nIPaccountability  form/record.
4. Further guidance and information fo r the final disposition of unused study  
interventions are provided in the I P manual .
5.Any storage conditions stated in the SRSD will be superseded by  the storage 
conditions stated on the product label. 
6.Study  interventions should be stored in their original containers and in accordance 
with the labels. 
7.Deviations from the storage requirements, including an y actions taken, must be 
documented and reported to Pfizer upon discovery.  The site should actively pursue 
options for returning the study  intervention to the storage conditions described in the 
labeling, as soon as possible.   Once an excursion is identified, the study  intervention
must be quarantined and not used until Pfizer provides permission to use the study  
intervention.  I t will not be considered a protocol deviation if Pfizer approves the use 
of the study  intervention after the temperature excursion.   Use of the stud y 
intervention prior to Pfizer approval will be considered a protocol deviation. Specific 
details regarding the definition of an excur sion and information the site should report 
for each excursion will be provided to the site in the I P m
anual. 
8.The Sponsor or designee will provide guidance on the destruction of unused study  
intervention (eg, at the site).  If destruction is authorized to take place at the 
investigator site, the investigator must ensure that the materials are destro yed in 
compliance with applicable environmental regulations, institutional policy , and any  
special instructions provided by Pfizer , and all destruction must be adequately  
documented.
6.2.1. Preparation and Dispensing
Within this protocol, preparation refers to the investigator site activities performed to make 
the IPready for administration or dispensing to the participant by qualified staff.  Dispensing 
is defined as the provision of IP, concomitant treatments, and accompany ing information by  
qualified staff member(s) to a healthcare provider, participant in accordance with this 
protocol.  L ocal health authority  regulations or investigator site guidelines may  use 
alternative terms for these activities.
Tablets will be dispensed at the CRU in the individual dosing containers by 2 operators, one
of whom is an appropriately qualified and experienced member of the study  staff 
(eg,physician, nurse, phy sician’s assistant, nu rse practitioner, pharmacy  assistant/technician, 
or pharmacist).  The tablets will be provided in unit dose containers and labeled in 
accordance with Pfizer regulations and the clinical site’s labeling requirements. 

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 30Only  qualified personnel who are famili ar with procedures that minimize undue exposure to 
themselves and to the environment should undertake the preparation, handling, and safe 
disposal of chemotherapeutic agents .
6.3.Measures to Minimize Bias: Randomization and Blinding
6.3.1. Allocation to Investigation al Product
The investigator’s knowledge of the treatment should not influence the decision to enroll a 
particular participant or affect the order in which participant s are enrolled.
The investigator will assign participant numbers to the participant s as th ey are screened for 
the study .  Pfizer will provide a randomization schedule to the investigator and, in 
accordance with the randomization numbers, the participant will receive the study  treatment 
regimen assigned to the corresponding randomization number.
6.4.
Study Intervention Compliance
IPwill be administered under the supervision of investigator site personnel.  The oral cavity  
of each participant will be examined following dosing to ensure the IPwas taken.
6.5.Concomitant Therapy
For participant s with normal hepatic function (Cohort 2), use of prescription or 
nonprescription drugs and dietary and herbal supplements are prohibited within 7 days or 
5half-lives (whichever is longer) prior to the first dose of IP.  Limited use of nonprescription
medications thatare not believed to affect participant safet y or the overall results of the study 
may be permitted on a case-by-case basis following approval by  the Sponsor .
Acetaminophen /paracetamol may be used at doses of 1g/day .
For participant s with severe hepatic impairment (Cohort 1), stable concomitant medications 
may be given if they  are considered necessary  for the welfare of the participants (eg, standard 
therap y for the underl ying diseases), considering these medications are not contraindicated 
with dacomit inib and are unlikely  to interfere with the PK of dacomitinib.
All concomitant treatments taken during the study  must be recorded with indication, daily  
dose, and start and stop dates of administration.  All participant s will be questioned about 
concomitant treatment at each clinic visit.
Treatments taken within 28 days before the first dose of IPwill be documented as a prior 
treatment.  Treatments taken after the first dose of IPwill be documented as concomitant 
treatments.
6.6. Dose Modification
Participant sin this study  will receive a single oral dose of 30 mg dacomitinib. No dose 
modification is allowed.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 316.7.Intervention A fter the End of the Study
No intervention will be provided to study participants at the end of the study .
7.DISCONTINUATION OF S TUDY INTERVEN TION AND PARTICIPANT
DISCONTINUATION/WITH DRAWAL
7.1.Discontinuation of Study Intervention
Not applicable since this is a single dose stud y.
7.2.Participant Discontinuation/ Withdrawal F rom the Study
A participant may  withdraw from the study  at an y time at his/her own request, or may  be 
withdrawn at an y time at the discretion of the investigator for safety, behavioral, compliance, 
or administrative reasons.
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit should 
be conducted. See the SoA for assessments to be collected at the time of study  
discontinuation and follow- up and for an y further evaluations that need to be completed. 
The early  discontinuation visit applies only  to partici pants who are randomized and then are 
prematurel y withdrawn from the study.
  Participants should be questioned regarding their 
reason for withdrawal.   The participant will be permanently  discontinued from the study  at 
that time.
If a participant withdraws from the study , he/she may  request destruction of any  remaining 
samples, but data alread y generated from the samples will continue to be available, and may 
be used to protect the integrity  of existing anal yses.  The investigator must document any  
such requ ests in the site study  records.
If the participant withdraws from the study  and also withdraws consent (see below) for 
disclosure of future information, no further evaluations should be performed and no 
additional data should be collected.  The Sponsor may retain and continue to use any  data 
collected before such withdrawal of consent.
When a 
participant withdraws from the study  because of an SAE, the SAE must be recorded 
on the CRF and reported on the Clinical Trial ( CT)SAE Report.
Lack of completion of a ll or an y of the withdrawal/earl y termination procedures will not be 
viewed as protocol deviations so long as the participant ’s safet y was preserved.
Withdrawal of Consent: 
Participant s who request to discontinue receipt of study  treatment will remain in 
the study  
and must continue to be followed for protocol -specified follow -up procedures.  The onl y 
exception to this is when a participant specificall y withdraws consent for any further contact 
with him or her or persons previously  authorized by  the partici pant to provide this 

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 32information.  Participant s should notify  the investigator in writing of the decision to 
withdraw consent from future follow- up, whenever possible.  The withdrawal of consent 
should be explained in detail in the medical records by  the i nvestigator, as to whether the 
withdrawal is only  from further receipt of IPor also from study  procedures and/or 
posttreatment study  follow -up, and entered on the appropriate CRF page.  In the event that 
vital status (whether the participant is alive or d ead) is being measured, publicly  available 
information should be used to determine vital status only  as appropriatel y directed in 
accordance with local law.
7.3.Lost to Fol lowup 
A participant will be considered lost to follow- up if he or she repeatedl y fails to return for 
scheduled visits and is unable to be contacted b y the study  site.
The following actions must be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible and counsel the participant on the importance of maintaining the 
assigned visit schedule and ascertain whether or not the participant wishes to and/or 
should continue in the study ;
Before a parti cipant is deemed lost to follow -up, the investigator or designee must 
make every  effort to regain contact with the participant (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing 
address or local equivalent methods). These contact attempts should be documented 
in the participant’s medical record ;
Should the participant continue to be unreachable, he/she will be considered to have 
withdrawn from the study. 
Discontinuation of specific sites or of the study  as a whole ishandled as part of Appendix 1 .
8.STUDY ASSESSMENTS AND PROCEDURES
Participant s will be screened within 28 days prior to administration of the IPto confirm that 
they meet the study  population criteria for the study.  The investigator (or an appropriate 
delegate at the investigator site) must obtain a signed and dated ICDbefore performing any  
study -specific procedures.
  If the time between screening and dosing exceeds 28 days as a 
result of unexpected delays (eg, delay ed drug s hipment), then participant s do not require 
rescreening if the laboratory  results obtained prior to first dose administration meet eligibility  
criteria.
Study  procedures and their timing are summarized in the SoA. Protocol waivers or 
exemptions are not allowed.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 33Immediate safety  concerns should be discussed with the Sponsor immediately  upon 
occurrence or awareness.
Adherence to the study design requirements, including those specified in the SoA, is essential 
and required for stud y conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility  or record reasons for 
screening failure, as applicable.
Every  effort should be made to ensure that protocol -required tests and procedures are 
completed as described.  However, it is anticipat ed that from time to time there may  be 
circumstances outside the control of the investigator that may  make it unfeasible to perform 
the test.  I n these cases, the investigator must take all steps necessary  to ensure the safet y and 
well-being of the partici pant.  When a protocol -required test cannot be performed, the 
investigator will document the reason for the missed test and an y corrective and preventive 
actions that he or she has taken to ensure that required processes are adhered to as soon as 
possible.  The study  team must be informed of these incidents in a timely  manner.
Ifan intravenous (IV) catheter is utilized for blood sample collections, ECGs and vital sign 
assessments ( pulse rate and BP) should be collected prior to the insertion of the cathete r .
For samples being collected and shipped, detailed collection, processing, storage, and 
shipment instructions and contact information will be provided to the investigator site prior 
to initiation of the study .
The total blood sampling volume for individu al participant s in this study  is approximately  
140mL.  The actual collection times of blood sampling may  change.  Additional blood 
samples may  be taken for safet y assessments at times specified by Pfizer, provided the total 
volume taken during the study does not exceed 550 mLduring an y period of 60 consecutive 
days.
To prepare for stud y participation, participant s will be instructed on the information in the 
Lifesty le Considerations and Concomitant Therapy sections of the protocol.
8.1.Efficacy Assessments
Efficacy  asse ssments are not applicable in this study .
8.2.Safety Assessments
Planned time points for all safety  assessments are provided in the SoA .  Unscheduled clinical 
laboratory  measurements may  be obtained at any  time during the stud y to assess any 
perceived safety  concerns.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 348.2.1. Physical Examinations
A complete physical examination will include , at a minimum, head, ears, eyes, nose, mouth, 
skin, hear t and lung examinations, ly mph nodes, and gastrointestinal, musculoskeletal, and 
neurological s ystems. 
A brief physical examination will include, at a minimum, assessments of general appearance, 
the respiratory  and cardiovascular s ystems, and participant -reported s ymptoms.
Physical examinations may  be conducted by  a ph ysician, trained ph ysician ’s assistant, or 
nurse practitioner as acceptable according to local regulation. 
Height and body  weight will also be measured and recorded as per the SoA .  For measuring 
body  weight, a scale with appropriate range and resolution is used and must be placed on a 
stable, flat surface. Participant s must remove shoes, bulky  layers of clothing, and jackets s
o
that only  light c lothing remains.  They  must also remove the contents of their pockets and 
remain still during measurement of body  weight. 
8.2.2. Vital Signs
Supine BPwill be measured with the participant ’s arm supported at the level of the heart
, and 
recorded to the nearest mm Hgafter approximately  5minutes of rest .  The same arm 
(preferabl y the dominant arm) will be used throughout the study
. Participant s should be 
instructed not to speak during measurements.
The same properl y sized and calibrated BP cuff will be used to m easure BP each time.  The 
use of an automated device for measuring BP and pulse rate is acceptable; however, when 
done manuall y, pulse rate will be measured in the brachial/radial artery  for at least 
30seconds.  When the timing of these measurements coinc ides with a blood collection, BP 
and pulse rate should be obtained prior to the nominal time of the blood collection.
Additional collection times, or changes to collection times, of BPand pulse rate will be 
permitted, as necessary , to ensure appropriate collection of safety  data.
8.2.3. Electrocardiograms
Single or triplicate 12-Lead ECG should be collected at times specified in the SoA section of 
thisprotocol using an ECG machine that automatically  calculates the he art rate and measures 
PR, QT, and corrected QT (QTc)intervals and QRS complex .All scheduled ECGs should 
be performed after the participant has rested quietly  for at least 10 minutes in a supine 
position. 
Triplicate 12 -lead ECGs will be obtained approxi mately  2to 4minutes apart; the average of 
the triplicate ECG measurements collected on Day 1 at predose will serve as each 
participant ’s time -controlled baseline QTc value.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 35To ensure safet y of the participant s, a qualified individual at the investigator site will make 
comparisons to baseline measurements.  Additional ECG monitoring will occur if a) a 
postdose QTc interval is increased b y 30msecfrom the baseline andis >450 msec; or b) an 
absolute QTc value is 500msecfor any  scheduled ECG. If eithe r of these conditions 
occurs, then 2 additional ECGs will be collected approximately  2to 4minutes apart to 
confirm the original measurement. If the QTc values from these repeated ECGs remain 
above the threshold value, then a single ECG must be repeated at least hourly  until QTc 
values from 2 successive ECGs fall below the threshold value that triggered the repeat 
measurement.
If a postdose QTc interval remains30msecfrom the baseline andis >450 msec; or b) an 
absolute QTc value is 500msecfor any  scheduled ECG for greater than 4 hours (or sooner ,
at the discretion of the investigator), or QTc intervals get progressivel y longer, the participant
should undergo continuous ECG monitoring.  A cardiologist should be consulted if QTc 
intervals do not retur n to less than the criterion listed above after 8 hours of monitoring (or 
sooner ,at the discretion of the investigator).
In some cases, it may  be appropriate to repeat abnormal ECGs to rule out improper lead 
placement as contributing to the ECG abnormali ty.  It is important that leads beplaced in the 
same positions each time in order to achieve precise ECG recordings.  If a machine -read QTc 
value is prolonged, as defined above, repeat measurements may  not be necessary  if a 
qualified medical provider’s interpretation determines that the QTc values are in the 
acceptable range.
ECG values of potential clinical concern arelisted in Appendix 7.
8.2.4. Clinical Safety Laboratory Assessments
See Appendix 2 for the list of clinical safet y laboratory  tests to be performed and the SoA for 
the timing and frequency.
The investigator must review the laboratory  report, document this review, and record any  
clinically  relevant changes occurring during the study  in the AE section of the CRF. 
Clinically  significant abnormal laboratory  test findings are those which are not associated 
with the underly ing disease, unless judged by  the investigator to be more severe than 
expec ted for the participant ’s condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participation in the study  or within 28daysafter dacomitinib dosing should be repeated until 
the values return to normal or baseline or are no longer considered clinically  significant by  
the investigator or medical monitor.
If such values do not return to normal/baseline within a period of time judged reasonable by  
the investigator, the etiology  should be identified and the Sponsor notified.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 36All protocol -required laboratory  test assessments, as defined in Appendix 2 , must be 
conducted in accordance with the laboratory  manual and the SoA .
If laboratory  test values from non- protocol -specified laboratory  assessments performed at the 
institution’s local laboratory  require a change in participant management or are considered 
clinically  significant b y the investigator (eg, SAE or AE or dose modification), then the 
results must be recorded in the CRF.
Participant s may  undergo random urine drug testing at the discretion of the investigator.  
Drug testing conducted prior to dosing must be negative for participant s to receive IP. 
8.3. Adverse Events and Serious Adverse Events
The definitions of an AE and an SAE can be found in Appendix 3 .
AEswill be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or 
the participant ’s legally  authorized representative).
The investiga tor and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible to pursue 
and obtain adequate information both to determine the outcome and to assess whether i t 
meets the criteria for classification as an SAE or that caused the participant to discontinue the 
study  (see Section 7).
In addition, the investigator may  be requested by  Pfizer Safet y to o btain specific follow -
up 
information in an expedited fashion.
8.3.1. Time Period and Frequency for C ollecting AE and SAE Information
The time period for actively  eliciting and collecting AEs and SAEs (“active collection 
period”) for each participant begins from t he time the participant provides informed consent, 
which is obtained before the participant ’s participation in the study  (ie, before undergoing 
any study -related procedure and/or receiving IP), through and including a minimum of 
28calendar day s, except as indicated below, after the last administration of the IP.
For participant s who are screen failures, the active collection period ends when screen failure 
status is determined.
Medical occurrences that begin before the start of study  intervention but after obtaining 
informed consent will be recorded on the Medical History /Current Medical Conditions 
section of the CRF, not the AE section.
Follow -up by  the investigator continues throughout and after the active collection period and 
until the event or its sequelae resolve or stabilize at a level acceptable to the investigator, and 
Pfizer concurs with that assessment.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 37Investigators are not obligated to activel y seek AE or SAE after conclusion of the study 
participation. However, if the investigator learns of an y SAE, including a death, at an y time 
after a participant has been discharged from the study , and he/she considers the event to be 
reasonabl y related to the study  intervention or study  participation, the investigator must 
promptly  notify  the Sponsor .
8.3.1.1. Repor ting SAEs to Pfizer Safety
All SAEs occurring in a participant during the active collection period are reported to Pfizer 
Safety  on the CT SAE Report Form immediatel y and under no circumstance should this 
exceed 24 hours, as indicated in Appendix 3 . The investigator will submit any  updated SAE 
data to the Sponsor within 24 hours of it being available.
SAEs occurring in a participant after the active collection period has ended are reported to 
Pfizer Safety  if the investigato r becomes aware of them; at a minimum, all SAEs that the 
investigator believes have at least a reasonable possibility of being related to IPmust be 
reported to Pfizer Safet y.
8.3.1.2. Recording Nonserious AEs and SAEs on the CRF
During the active collection period , both nonserious AEs an d SAEs are recorded on the CRF.
8.3.2. Method of Detecting AEs and SAEs
The method of recording, evaluating, and assessing causality  of AE sand SAE sand the 
procedures for completing and transmitting SAE reports are provided in Appendix 3 .
Care will be taken not to introduce bias when detecting AEs and/or SAEs.   Open -ended and 
nonleading verbal questioning of the participant is the preferred method to inquire about 
AEoccurrences.
8.3.3. Follow -up of AEs and SAEs
After the initial AE/SAE report, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. For each event, the investigator must pursue and 
obtain adequate information until resolution, stabilization, the event is ot herwise explained, 
or the participant is lost to follow- up (as defined in Section 7.3).
In general, follow -
up information will include a description of the event in sufficient detail to 
allow for a complete medical assessment of the case and independent determination of 
possible causality .  An y information relevant to the event, such as concomitant medications 
and illnesses, must be provided.  In the case of a participant death, a summary of av ailable 
autopsy  findings must be submitted as soon as possible to Pfizer Safety . 
Further information on follow -up procedures is given in Appendix 3 .

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 388.3.4. Regulatory Reporting Requirements for SAEs
Prompt notification by  the investigator to the Sponsor of an SAE is essential so that legal 
obligations and ethical responsibilities towards the safet y of participants and the safet y of a 
study  intervention under clinical investigation are met.
The Sponsor has a legal responsibility  to notify  both the local regulatory  authority  and other 
regulatory  agencies about the safet y of a stud y intervention under clinical investigation. The 
Sponsor will comply with country -specific regulatory  requirements relating to safet y 
reporting to the regulatory  authorit y, institutional review boards (IRB s)/ethics committees 
(EC
s), and investigators.
Investigator safety  reports must be prepared for suspected unexpected serious adverse 
reactions (SUSAR s) according to local regulatory  requirements and Sponsor policy  and 
forwarded to investigators as necessary .
An investigator who receives an investigator safety report describing a nSAE or other 
specific safet y information (eg, summary or listing of SAEs) from the Sponsor will review 
and then file it along with the investigator’s brochure and will notify  the IRB/EC, if 
appropriate a ccording to local requirements.
8.3.5. Exposure During Pregnancy or Breastfeeding, and Occupational Exposure
Exposure to the IPunder study  during pregnancy  or breastfeeding and occupational exposure 
are reportable to Pfizer Safet y within 24 hours of investigator awareness.
8.3.5.1. Exposure During Pregnancy
Details of all pregnancies in female partners of male particip antswill be collected after the 
start of study  intervention and until 3weeks after the last dose.
If a pregnancy  is reported, the investigator sh ould inform the Sponsor within 24 hours of 
learning of the pregnancy  and should follow the procedures outlined in Appendix 4 .
Abnormal pregnancy  outcomes (eg, sp ontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy ) are considered SAEs.
8.3.5.2. Exposure During Breastfeeding
Scenarios of exposure during breastfeeding must be reported, irrespective of the presence of 
an associated SAE, to Pfiz er Safet y within 24 hours of the investigator’s awareness, using the 
CT SAE Report Form.  An exposure during breastfeeding report is not created when a Pfizer 
drug specifically  approved for use in breastfeeding women (eg, vitamins) is administered in 
accor d with authorized use.  However, if the infant experiences an SAE associated with such 
a drug’s administration, the SAE is reported together with the exposure during breastfeeding.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 398.3.5.3. Occupational Exposure
An occupational exposure occurs when, during the perf ormance of job duties, a person 
(whether a healthcare professional or otherwise) gets in unplanned direct contact with the 
product, which may  or may  not lead to the occurrence of an AE.
An occupational exposure is reported to Pfizer Safety  within 24 hours of the investigator’s 
awareness, using the CT SAE Report Form, regardless of whether there is an associated 
SAE.  Since the information does not pertain to a participant enrolled in the study , the 
information is not recorded on a CRF; however, a copy  of th e completed CT SAE Report 
Form is maintained in the investigator site file .
8.3.6. Medication Errors
Medication errors may  result from the administration or consumption of the IPby the wrong 
participant , or at the wrong time, or at the wrong dosage strength.
Exposures to the IPunder study  may  occur in clinical trial settings, such as medication 
errors.
Safety Event Recorded on the CRF Reported on the CT SAE Report Form  to 
Pfizer Safety Within 24 Hours of Awareness
Medication errors All (regardless of whether 
associated with an AE)Only if associated with an SAE
Medication errors include:
Medication errors involving participant exposure to the IP;
Potential medication errors or uses outside of what is foreseen in the protocol that do 
or do not involve the studyparticipant .
Such medication errors occurring to a study participant are to be captured on the medication 
error page of the CRF, which is a specific version of the AE page.
In the event of a medication dosing error, the Sponsor should be notified immedia tely.
Whether or not the medication error is accompanied by  an AE, as determined by  the 
investigator, the medication error is recorded on the medication error page of the CRF and, if 
applicable, an y associated AE(s), serious and nonserious, are recorded on an AE page of the 
CRF.
Medication errors should be reported to Pfizer Safety within 24 hours on a CT SAE Report 
Form only when associated with an SAE.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 408.4.Treatment of Overdose
For this study , any  dose of dacomitinib greater than 30 mgwill be considered an overdose.
The Sponsor does not recommend specific treatment for an overdose.
In the event of an overdose, the investigator/treating ph ysician should:
1.Contact the medical m onitor immediately .
2.Closely  monitor the participant for an y AEs/SAE sand laboratory  abnormalities until 
dacomitinib can no longer be detected s ystemically  (at least 17days, 5 × dacomitinib 
half-life).
3.Obtain a 
blood sample for PK anal ysis within 1day from the date of the last dose of 
study  intervention if requested by  the medical m onitor (determined on a case -by-case 
basis).
4.Document the quantit y of the excess dose as well as the duration of the overdose in 
the CRF.
5.Overdose is reportable to Safety  only  when associated with a nSAE.
Decisions regarding dose interruptions or modifications wi ll be made by  the investigator in 
consultation with the 
medical m onitor based on the clinical evaluation of the participant.
8.5.Pharmacokinetics 
8.5.1. Pharma cokinetic Assessment of Dacomitinib and PF -05199265
Blood samples of approximately  3mL, to provide a minimum of 1 mL of plasma , will be 
collected 
into appropriately  labeled tubes containing dipotassium ethy lenediamine tetraacetic 
acid (K2EDTA ) at each specified time point for measurement of plasma concentrations of 
dacomitinib and its metabolite PF-05199265 asspecified in the SoA .  Instructions for the 
collection and handling of biological samples will be provided in the lab oratory manual or by  
the 
Sponsor . The actual date and time (24 -hour clock time) of each samp le will be recorded.
The actual times may  change, but the number of samples will remain the same.  All efforts 
will be made to obtain the samples at the exact nominal time relative to dosing.  Collection of 
samples up to and including 10 hours after dose administration that are obtained within 
10% of the nominal time (eg, within 6 minutes of a 60 -minute sample) relative to dosing will 
not be captured as a protocol deviation, as long as the exact time of the collection is noted on 
the source document and dat
a collection tool (eg, CRF).   Collection of samples more than 
10hours 
after dose administration that are obtained 1hour away from the nominal time 
relative to dosing will not be captured as a protocol deviation, as long as the exact time of the 
collecti on is noted on the source document and data collection tool (eg, CRF ). 

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 41Samples will be used to evaluate the PK of dacomitinib and PF -05199265. Samples 
collected for anal yses of dacomitinib and PF -05199265 plasma concentration may  also be 
used to evaluate safet y or efficacy aspects related to concerns arising during or after the 
study , for metabolite identification and/or evaluation of the bioanal ytical method, or for other 
internal exploratory  purposes.
Genetic anal yses will not be performed on these plasmasamples unless consent for this was 
included in the informed consent .  Participant confidentiality  will be maintained.
Samples collected for measurement of plasma concentrations of dacomitinib and 
PF-
05199265 will be analyzed using a validated analy tical method in compliance with 
applicable standard operating procedures (SOPs).
The PK samples must be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity .  Any deviations from the PK sample 
handling procedure (eg, sample collection and processing steps, interim storage or shipping 
conditions), including any actions taken, must be documented and reported to the Sponsor .  
On a case -by-case basis, the 
Sponsor may make a determination as to whether sample 
integrit y has been compromised.
8.5.2. Protein Binding Assessment
Blood samples (10 mL of blood to obtain 4 ml of plasma) for protein binding anal ysis will be 
collected into appropriately  labeled tubes containing K 2EDTA at times specified in the SoA.  
The actual times may  change but the number of samples will remain the same.  All efforts 
will be made to obtain the protein binding samples at the exact nominal time relative to 
dosing.  However, samples obtained w ithin 10% of the nominal time (eg, within 6 minutes of 
a 60 minute sample) from dosing will not be captured as a protocol deviation, as long as the 
exact time of the sample collection is noted on the source document and data collection tool 
(eg, CRF).
Samp les will be analy zed using a validated anal ytical method in compliance with Pfizer 
SOPs.
The blood samples must be processed and shipped as indicated in the instructions provided to 
the investigator site to maintain sample integrity .  Any deviations from t he sample handling 
procedure (eg, sample collection and processing steps, interim storage or shipping 
conditions), including any actions taken, must be documented and reported to the Sponsor .  
On a case -by-case basis, the 
Sponsor may make a determination a s to whether sample 
integrit y has been compromised.
8.6.Pharmacodynamics
Pharmacod ynamic (PD) parameters are not evaluated in this study .

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 428.7.Genetics
8.7.1. CYP2D6 Genotyping Analysis
A 3-mL blood sample for deoxyribonucleic acid ( DNA) isolation will be collected .  DNA 
samples will be anal yzed for the purpose of determining the genot ype of CYP2D6 .
Genes for other drug -metabolizing enzy mes or transporters suspected to be involved in the 
metabolism and/or excretion of dacomitinib may  also be evaluated.  No other genes will be 
analyzed.
In the event of DNA extraction failure, a replacement genetic blood sample may  be requested 
from the participant.
See Appendix 5 for information regarding genetic research.  Details on processes for 
collection and shipment of these samples can be found in the laboratory  manual or by  the 
Sponsor .
8.7.2. Banked Biospecimens for Genetics
A 4-mL blood sample optimized for DNA isolation Prep D1 will be collected as local 
regulations and IRBs/E Cs allow.
Banked biospecimens may be used for research related to drug response.  Genes and other 
analytes (eg
,proteins, ribonucleic acid (RNA ), nondrug metabolites) may  be studied using 
the banked samples. 
Unless prohibited by  local regulations or IRB/EC decision, participant s will be asked to 
indicate on the consent document whether they  will allow their banked biospecimens to also 
be used to design and conduct research in order to gain a further understanding of other 
diseases and to advance science, including development of other medicines for patients.  This 
component of the sampling banking is optional for participants; they  may  still participate in 
the study  even if they  do not agree to th e additional research on their banked biospecimens .  
The optional additional research does not require the collection of any  further samples.
See Appendix 5 for informa tion regarding genetic research .  Details on processes for 
collection and shipment of these samples can be found in laboratory  manual or by  the 
Sponsor .
8.8.Biomarkers
Biomarkers are not evaluated in this study .
8.9.Health Economics
Health 
economics/ medical resource utilization and health e conomics parameters are not 
evaluated in this study .

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 439.STATISTICAL CONSIDERATIONS
Detailed methodology  for summary  and st atistical anal yses of the data collected in this study  
is outlined here and further detailed in a statistical anal ysis plan (SAP), which will be 
maintained by  the Sponsor .  The SAP may  modify  what is outlined in the protocol where 
appropriate; however, any major modifications of the primary  endpoint definitions or their 
analyses will also be ref lected in a protocol amendment.
9.1.Statistical Hypotheses
Not applicable .
9.2.Sample Size Determination
Approximately 18participant s will be enrolled into the study  to ens ure 6 PK evaluable 
participant s in each of the 2 c ohorts.  This sample size is consistent with recommendations 
from the Food and Drug Administration ( FDA )Guidance for Industry : Pharmacokinetics in 
Patients with I mpaired Hepatic Function: Study  Design, Dat a Analy sis, and I mpact on 
Dosing and Labeling3(issued by  Center for Drug Evaluation and Research [CDER]/ Center 
for Biologics Evaluation and Research [CBER ], May  2003). 
9.3.Populations for Analysis
Population Desc ription
Safety All participants assigned to dacomitinib and who take 1 dose of 
dacomitinib .
PK Concentration All participants who take 1 dose of dacomitinib and have at 
least 1 dacomitinib plasma concentration.
PK parameter All participants who take 1 dose of dacomitinib and have at 
least 1 dacomitinib plasma PK parameters of primary  interest.
9.4. Statistical Analyses
The SAP will be developed and finalized before database lock and will describe the 
participant populations to be included in the analy ses, a nd procedures for accounting for 
missing, unused, and spurious data. This section is a summary  of the planned statistical 
analyses of the primary  and secondary  endpoints.
9.4.1. Efficacy Analyses
An e fficacy  anal ysis is not applicable to this study . 
9.4.2. Safety Anal yses
AEs, ECGs, BP , pulse rate , and safety  laboratory  test data will be reviewed and summarized 
on an ongoing basis during the stud y to evaluate the safet y of participant s.  Any  clinical 
laboratory test, ECG, BP, and 
pulse rate abnormalities of potential c linical concern will be 
described.  Safet y data will be presented in tabular and/or graphical format and summarized 
descriptivel yby cohort , where appropriate.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 44Medical history  and phy sical examination information , as applicable, collected during the 
course of the stud y will be considered source data and will be required to be reported , unless 
otherwise noted.  However, an y untoward findings identified on phy sical examination s 
conducted during the active collection period will be captured as AEs, if those fi ndings meet 
the definition of an AE. Data collected at Screening that areused for inclusion/exclusion 
criteria, such as laboratory  data, ECGs ,and vital signs , will be considered source data, and 
will be required to be reported , unless otherwise noted.  Demographic data collected at 
Screening will be reported .
9.4.2.1. Electrocardiogram Analyses
Changes from baseline for the ECG parameters QT interval, heart rate, QTc interval, PR 
interval, and QRS complex will be summarized by cohort and time.
The number (%) of p articipant s with maximum post -dose QTc values and maximum 
increases from baseline in the following categories will be tabulated by  cohort : 
Safety QTc Assessment
Degree of Prolongation Mild (msec) Moderate (msec) Severe (m sec)
Absolute value >450-480 >480-500 >500
Increase from baseline 30-60 >60
In addition, the number of participant s with uncorrected QT values >500 msecwill be 
summarized.
9.4.3. Other Analyses 
PGx data will be collected and retained for future anal yses, but will not be anal yzed, 
specific ally, for this study. 
9.4.3.1. Pharmacokinetic Analyses
The effect of hepatic impairment on PK parameters will be assessed b y constructing 
90% confidence intervals (CIs)around the estimated difference between the Test ( severe 
hepatic impair ment cohort ; Cohort 1) and the Reference (normal hepatic function ; Cohort 2) 
using a one -way analysis of variance (ANOVA )model based on natural log transformed 
data. Only participant s with CYP2D6 EM and IM in each cohort will be included in this 
analysis.
One-way ANOVA will be used to compare the natural log transformed AUC inf, AUC lastand 
Cmax, and AUC inf, u, AUC last,uand C max,uof dacomitinib and PF-05199265, as data permit, for 
severe hepatic impairment cohort (Test) to the normal hepatic function cohort (Reference). 
Estima tes of the adjusted mean differences (Test
-Reference) and corresponding 90% CIs will 
be obtained from the model.  The adjusted mean differences and 90% CIs for the differences 
will be exponentiated to provide estimates of the ratio of adjusted geometric me ans 
(Test/Reference) and 90% CIs for the ratios as a percentage . 

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 45The dacomitinib PK parameters ( AUC inf, AUC inf,u, AUC last, AUC last,u, Cmax, Cmax,u, Tmax, t½, 
CL/F,CL u/F, V z/F, and V z,u/F) and PF-05199265 PK parameters ( AUC inf, AUC inf,u, AUC last, 
AUC last,u, Cmax, Cmax,u, Tmax, t½) will be summarized descriptivel y by cohort .  Boxplots of 
mean, median and individual participant parameters will be made bycohort for AUC inf, 
AUC inf,u, AUC last, AUC last,u, Cmax, and C max,u.  Similar presentations will also be made for 
other PK parameters, if considered relevant.   Dacomitinib and PF -05199265 total and 
unbound concentrations will be listed and summarized descriptively  by PK sampling time 
and cohort .  Summary  profiles (means and medians) of the dacomitinib and PF - 05199265
concentration -time data will be plotted bycohort on linear and semi -log scale .  Individual 
participant concentration time profiles will be also presented.   For summary  statistics and 
summary  plots by  sampling time, the nominal PK sampling time will be used, for individual 
participant plots by  time, the actua lPK sampling time will be used.
9.4.3.2. Pharmacodynamic Analyses
Not applicable .
9.5.Interim 
Analyses
No formal interim anal ysis will be conducted for this study . As this is an open- label study ,
the Sponsor may conduct unbli nded reviews of the data during the course of the study  for the 
purpose of safet y assessment, facilitating dose selection decisions, 
and/or support ingclinical 
development.
9.5.1. Data Monitoring Committee
This study  will not use a data monitoring committee (DMC ).

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 4610. SUPPORTING DOCUMENTA TION AND OPERATIONAL CONSIDERATIONS
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1. Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with th e following:
Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines ;
Applicable International Council for Harmonisation (I CH) Good Clinical Practice 
(GCP) g uidelines;
Applicable laws and regulations , including applicable privacy  laws .
The protocol, protocol amendments, I CD, IB, and other relevant documents 
(eg,advertisements) must be reviewed and approve d by the Sponsor and submitted to an 
IRB/EC by  the investigator and reviewed and approved by  the IRB/EC before the study  is 
initiated.
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study  participants.
The investigator will be responsible for the following:
Providing written summaries of the status of the study  to the IRB/EC annually  or 
more frequently in accordance with t he requirements, policies, and procedures 
established by  the IRB/EC ;
Notify ing the IRB/EC of SAEs or other significant safet y findings as required by 
IRB/EC procedures;
Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 Code of Federal Regulations ( CFR ), ICH guidelines, the I RB/EC, 
European regulation 536/2014 for clinical studies (if applicable), and all other 
applicable local regulations.
10.1.1.1. Reporting of Safety Issues and Serious Breaches of the Protocol or ICH GC P
In the event of an y prohibition or restriction imposed (ie, clinical hold) b y an applicable 
regulatory  authorit y in any area of the world, or if the investigator is aware of an y new 
information that might influence the evaluation of the benefits and risk s of the IP, Pfizer 
should be informed immediatel y;  

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 47In addition, the investigator will inform Pfizer immediately  of any  urgent safet y measures 
taken b y the investigator to protect the study participants against an y immediate hazard, and 
of an y serious br eaches of this protocol or of ICH GCP that the investigator becomes aware 
of.
10.1.2. Financial Disclosure
Investigators and subinvestigators will provide the Sponsor with sufficient, accurate financial 
information as requested to allow the Sponsor to submit compl ete and accurate financial 
certification or disclosure statements to the appropriate regulatory  authorities. Investigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 yearafter completion of t he study .
10.1.3. Informed Consent Process
The investigator or his/her representative will explain the nature of the study to the 
participant or his/her legally  authorized representative and answer all questions regarding the 
study .
Participants must be informed that their participation is voluntary . Participants or their 
legally  authorized representative will be required to sign a statement of informed consent that 
meets the requirements of 21 CFR 50, local regulations, I CH guidelines, Health I nsurance 
Portabilit y and Accountability  Act (HIPAA) requirements, where applicable, and the IRB/EC 
or study  center.
The investigator must ensure that each study  participant or his or her legally  authorized 
representative is fully  informed about the nature and objectives of t he study , the sharing of 
data related to the study ,
and possible risks associated with participation, including the risks 
associated with the processing of the participant ’s personal data. 
The participant must be informed that his/her personal study -related data will be used by  the 
Sponsor in accordance with local data protection law. The level of disclosure must also be 
explained to the participant.
The participant must be informed that his/her medical records may  be examined by  Clinical 
Quality  Assuranc e auditors or other authorized personnel appointed by  the Sponsor , by 
appropriate IRB/EC members, and b y inspectors from regulatory authorities.
The investigator further must ensure that each study  participant or his or her legall y 
authorized representativ e is fully  informed about his or her right to access and correct his or 
her personal data and to withdraw consent for the processing of his or her personal data.
The medical record must include a statement that written informed consent was obtained 
before the participant was enrolled in the study  and the date the written consent was obtained.
The authorized person obtaining the informed consent must also sign the IC D
.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 48Participants must be reconsented to the most current version of the IC D(s) during their 
participation in the study .
A cop y of the IC D
(s) must be provided to the participant or the participant’s legall y 
authorized representative.
A participant who is rescreened is not required to sign another IC Difthe rescreening occurs 
within 28days from th e previous I CDsignature date.
The I CDwill contain a separate section that addresses the use of remaining mandatory  
samples for optional exploratory  research. The investigator or authorized designee will 
explain to each participant the objectives of the exploratory  research. Participants will be 
told that they  are free to refuse to participate and may  withdraw their consent at any  time and 
for an y reason during the storage period. A separate signature will be required to document a 
participant ’s agreeme nt to allow any  remaining specimens to be used for exploratory  
research. Participants who decline to participate in this optional research will not p rovide 
this separate signature.
10.1.4. Data Protection
All parties will comply  with all applicable laws, includin g laws regarding the implementation 
of organizational and technical measures to ensure protection of participant data.
Participants’ personal data will be stored at the study  site in en crypted electronic and/or paper
form and will be password protec ted or secured in a locked room to ensure that only  
authorized study  staff have access.  The study  site will implement appropriate technical and 
organizational measures to ensure that the personal data can be recovered in the event of 
disaster.  In the event of a potential personal data breach, the study  site shall be responsible 
for determining whether a personal data breach has in fact occurred and, if so, providing 
breach notifications as required by  law.
To protect the rights and freedoms of natural persons wi th regard to the processing of 
personal data, participants will be assigned a single, participant -specific numerical code. 
Any participant records or data sets that are transferred to the Sponsor will contain the 
numerical code; participant names will not be transferred. All other identifiable data 
transferred to the Sponsor will be identified b y this single, participant -specific code. The 
study  site will maintain a confidential list of participant s who participated in the study , 
linking each participant ’s numerical code to his or her actual identity . In case of data 
transfer, the Sponsor will protect the confidentiality  of participants’ personal data consistent 
with the c linical study agreement and applicable privacy  laws.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 4910.1.5. Dissemination of Clinical Stud y Data
Pfizer fulfills its commitment to publicly  disclose clinical study  results through posting the 
results of studies on www.clinicaltrials.gov (ClinicalTrials.gov), the European Clinical Trials 
Database (EudraCT), and/or www.pfizer.com, and other public registries in accordance with 
applicable local laws/regulations.  I n addition, Pfizer reports study  results outside of the 
requirements of local laws/regulations pursuant to its SOPs.
In all cases, stud y results are reported b y Pfizer in an objective, ac curate, balanced, and 
complete manner and are reported regardless of the outcome of the stud y or the country in 
which the study  was conducted.
www.clinicaltrials.gov
Pfizer posts clinical trial US Basic Results on www.clinicaltrials.gov for Pfizer -Sponsor ed 
interventional studies (conducted in patients) that evaluate the safet y and/or efficacy of a 
product, regardless of the geographical location in which the study is conducted.  US Basic 
Results are generall y submitted for posting within 1 year of the prim ary completion date 
(PCD) for studies in adult populations or within 6 months of the PCD for studies in pediatric 
populations.
PCD is defined as the date that the final participant was examined or received an intervention 
for the purposes of final collection of data for the primary  outcome, whether the clinical 
study  concluded according to the prespecified protocol or was terminated.
EudraCT
Pfizer posts European Union (EU) Basic Results on EudraCT for all Pfizer -Sponsor ed 
interventional studies that are in scope of EU requirements.  EU Basic Results are submitted 
for posting within 1 year of the PCD for studies in adult populations or within 6 months of 
the PCD for studies in pediatric populations.
www.pfizer.com
Pfizer posts public disclosure s ynopses (CSR synopses in which any  data that could be used 
to identify  individual participants have been removed) on www.pfizer.com for 
Pfizer -Sponsor ed interventional studies at the same time the US Basic Results document is 
posted to www.clinicaltrials.gov .
Document s within marketing authorization packages/submissions
Pfizer complies with the European Union Policy  0070, the proactive publication of clinical 
data to the European Medicines Agency  (EMA) website.   Clinical data, under Phase 1 of this 
policy ,includes cli
nical overviews, clinical summaries, C SRs, and appendices containing the 
protocol and protocol amendments, sample CRF s, and statistical methods. Clinical data, 
under Phase 2 of this policy ,includes the publishing of individual 
participant data. 
Policy 0070 applies to new marketing authorization applications submitted via the 

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 50centrali zed procedure since 01January 2015 and applications for line extensions and for new 
indications submitted via the centralized procedure since 01 July  2015.
Data Sharing
Pfizer provides researchers secure access to patient -level data or full CSRs for the purposes 
of “bona -fide scientific research” that contribute to the scientific understanding of the 
disease, target, or compound class. Pfizer will make available data from th ese trials 
24months after study  completion.  Patient -level data will be anon ymized in accordance with 
applicable privacy  laws and regulations. CSRs will have personall y identifiable information 
redacted.
Data requests are considered from qualified resear chers with the appropriate competencies to 
perform the proposed analy ses. Research teams must include a biostatistician. Data will not 
be provided to applicants with significant conflicts of interest, including individuals 
requesting access for commercia l/competitive or legal purposes.
10.1.6. Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF unless 
transmitted to the Sponsor or designee electronically  (eg, laboratory  data). The investigator 
is respon
sible for verify ing that data entries are accurate and correct by  physically  or 
electronically  signing the CRF.
The investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.
The investigator must ensu re that the CRFs are securel y stored at the study site in encr ypted 
electronic and/or paper form and are password protec ted or secured in a locked room to 
prevent access b y unauthorized third parties.
The investigator must permit study -related monitoring, audits, IRB/EC review, and 
regulatory  agency  inspections and provide direct access to source data documents.   This 
verification may  also occur after study  completion.  I t is important that the investigator(s) 
and their relevant personnel are available duri ng the monitoring visits and possible audits or 
inspections and that sufficient time is devoted to the process.
Monitoring details describing strategy  (eg, risk
-based initiatives in operations and quality  
such as risk management and mitigation strategies a nd analytical risk-based monitoring), 
methods, responsibilities ,and requirements, including handling of noncompliance issues and 
monitoring techniques (central, remote, or on -site monitoring) ,are provided in the 
monitoring plan/contracts.
The Sponsor or designee is responsible for the data management of this study ,including 
quality  checking of the data.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 51Study  monitors will perform ongoing source data verification to confirm that data entered 
into the CRF by  authorized site personnel are accurate, complet e, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study  is 
being conducted in accordance with the currently  approved protocol and any  other study  
agreements, I CH GCP, and all applicable re gulatory  requirements.
Records and documents, including signed IC Ds, pertaining to the conduct of this study  must 
be retained b y the investigator for 15years after study  completion unless local regulations or 
institutional policies require a longer retent ion period. No records may  be destroy ed during 
the retention period without the written approval of the Sponsor .No records may  be 
transferred to another location or party without written notification to the Sponsor .The 
investigator must ensure that the records continue to be stored securel y for aslong as they  are 
maintained.
When participant data are to be deleted, the investigator will ensure that all copies of such 
data are promptly  and irrevocabl y deleted from all systems.
The investigator(s) will notify  the Sponsor or its agents immediatel y of an y regulatory  
inspection notification in relation to the study .  Furthermore, the investigator will cooperate 
with the Sponsor or its agents to prepare the investigator site for the inspection and will allow
the Sponsor or its agent, whenever feasible, to be present during the inspection.  The 
investigator site and investigator will promptly  resolve any  discrepancies that are identified 
between the stud y data and the participant ’s medical records.  The invest igator will promptly  
provide copies of the inspection findings to the Sponsor or its agent.  Before response 
submission to the regulatory  authorities, the investigator will provide the Sponsor or its 
agents with an opportunity to review and comment on resp onses to an y such findings.
10.1.7. Source Documents
Source documents provide evidence for the existence of the participant and substantiate the 
integrit y of the data collected.   Source documents are filed at the investigator site.
Data reported on the CRF or ente red in the electronic CRF ( eCRF )that are transcribed from 
source documents must be consistent with the source documents or the discrepancies must be 
explained . The investigator may
 need to request previous medical records or transfer 
records, depending o n the study . Also, current medical records must be available.
10.1.8. Study and Site Closure
The Sponsor designee reserves the right to close the study  site or terminate the study  at an y 
time for an y reason at the sole discretion of the Sponsor .Study  sites will be closed upon 
study  completion. A study  site is considered closed when all required documents and study  
supplies have been collected and a stud y-site closure visit has been performed.
The investigator may  initiate study -site closure at any  time upon not ification to the contract 
research organization ( CRO )if requested to do so by  the responsible IRB/EC or if such 
termination is required to protect the health of study participants .

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 52Reasons for the earl y closure of a stud y site b y the Sponsor may include b ut are not limited 
to:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/EC or local health authorities, the Sponsor ’s procedures, or GCP guidelines;
Inadequate recruitment of participants by  the investigator;
Discontinua tion of further study  intervention development .
Study  termination is also provided for in the clinical study  agreement.  If there is any  conflict 
between the contract and this protocol, the contract will control as to termination rights.
10.1.9. Publication Policy
The results of this study  may  be published or presented at scientific meetings b y the 
investigator after publication of the overall study  results or 1year after end of the study  (or 
study  termination), whichever comes first. 
The investigator agrees to r efer to the primary  publication in any  subsequent publications 
such as secondary manuscripts, and submit s all manuscripts or abstracts to the Sponsor
30days before submission. This allows the Sponsor to protect proprietary  information and to 
provide comm ents and the investigator will, on request, remove an y previously  undisclosed 
confidential information before disclosure, except for an y stud y-or Pfizer -intervention 
related information necessary  for the appropriate scientific presentation or understandin g of 
the study  results.
For all publications relating to the stud y, the investigator will compl y with recognized ethical 
standards concerning publications and authorship, including those established by  the 
International Committee of Medical Journal Editors .
The Sponsor will comply with the requirements for publication of the over
all study  results 
covering all i nvestigator sites.   In accordance with standard editorial and ethical practice, the 
Sponsor will support publication of multicenter studies only  in their entirety  and not as 
individual site data.  In this case, a coordinating investigator will be designated by  mutual 
agreement.
Authorship of publications for the overall study  results will be determined by  mutual 
agreement and in line with International Committee of Medical Journal Editors authorship 
requirements. 
If publication is addressed in the clinical study  agreement, the publication policy  set out in 
this section will not apply.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 5310.1.10. Sponsor ’s Qualified Medical Personnel
The contact information for th e Sponsor ’s appropriately  qualified medical personnel for the 
study  is documented in the study  contact list located in the supporting study  
documentation/team SharePoint site/study  portal/clinical trial management sy stem 
(CTMS)/study  team on demand (S toD) system. 
To facilitate access to appropriatel y qualified medical personnel on stud y-related medical 
questions or problems, participant s are provided with a contact card.  The contact card 
contains, at a minimum, protocol and IPidentifiers, participant numbers, contact information 
for the investigator site, and contact details for a contact center in the event that the 
investigator site staff cannot be reached to provide advice on a medical question or problem 
originating from another healthcare professiona l not involved in the participant ’s 
participation in the study .  The contact number can also be used by  investigator staff if they  
are seeking advice on medical questions or problems; however, it should be used onl y in the 
event that the established commun ication pathways between the investigator site and the 
study  team are not available.  I t is therefore intended to augment, but not replace, the 
established communication pathway s between the investigator site and the study  team for 
advice on medical questi ons or problems that may arise during the stud y.  For sites other than 
a Pfizer CRU, the contact number is not intended for use b y the participant directly , and if a 
participant calls that number, he or she will be directed back to the investigator site.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 5410.2. A ppendix 2: Clinical Laboratory Tests
The following safet y laboratory  tests ( Table 2) will be performed at times defined in the SoA
section of this protocol.  Additional laboratory  resul ts may be reported on these samples as a 
result of the method of analy sis or the t ype of analy zer used by  the clinical laboratory ; or as 
derived from calculated values.  These additional tests would not require additional 
collection of blood.  Unscheduled clinical laboratory  measurements may  be obtained at an y 
time during the stud y to assess an y perceived safety  concerns.
Table 2. Protocol -Required Safety Laboratory Assessments
Hem atology Chemistry Urinalysis Other
Hem oglobin
Hem atocrit
RBC count
MCV
MCH
MCHC
Platelet count
PT/INR
WBC count
Total neutrophils (abs)
Eosinophils (abs)
Monocytes (a bs)
Basophils (a bs)
Lymphocytes (abs)BUN/urea and creatinine
Glucose (fasting)
Calcium
Sodium
Potassium
Chloride
AST, ALT
Total bilirubin
Alkaline phosphatase
Albumin
Total proteinpH
Glucose (qual)
Protein (qual)
Blood (qual)
Ketones
Nitrites
Leukocyte esterase
Urobilinogen
Urine bilirubin
MicroscopyaAt screen ingonly:
FSHb
Urine drug screeningc
Hepatitis B surface antigen
Hepatitis B core a ntibody
Hepatitis C antibody
Human immunodeficiency 
virus
Abbreviations: a bs= absolute; ALT = alanine aminotransferase; AS T = aspartate aminotransferase;
BUN =blood urea nitrogen; FSH = follicle -stimulating hormone; INR = international normalized ratio ;
MCH =mean corpuscular hemoglobin; MCHC = mean corpuscular hemoglobin concentration; 
MCV =mean corpuscular volume; qual = qualitative; PT=prothrombin time; RBC = red blood cell; 
WBC =white blood cell. 
a.Only if urine dipstick is positive for blood, pr otein, nitrites, or leukocyte esterase.
b.For confirmation of postmenopausal status only.
c.The minimum requirement for drug screening includes cocaine, tetrahydrocannabinol (THC), 
opiates/opioids, benzodiazepines, and amphetamines (others are site and study s pecific).
Investigators must document their review of each laboratory  safet y report.
Any remaining serum/plasma from samples collected for clinical safet y lab oratory  
measurements at baseline and at all times after dose administration may be retained and 
stored for the duration of the study .  Upon completion of the study , these retained safet y 
samples may  be used for the assessment of exploratory  safet y biomarkers or unexpected 
safet y findings .  These data will not be included in the clinical study  report ( CSR) .  Samples 
to be used for this purpose will be shipped to either a Pfizer-approved Biospecimen Banking 
System (BBS) facility  or other designated laboratory  and retained for up to 1year following 
the 
completion of the study .

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 5510.3. Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1. Definition of AE
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study 
participant, temporally associated with the use of study intervention, w hether or not 
considered related to the study  intervention.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) temporally  
associated with the use of study  intervention.
Events Meeting the AE Definition
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital sign measurements), 
including those that worsen from baseli ne, considered clinicall y significant in the 
medical and scientific judgment of the investigator (ie, not related to progression of 
underly ing disease).
Exacerbation of a chronic or intermittent preexisting condition including either an 
increase in frequen cy and/or intensity  of the condition.
New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug intera ction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as 
an AE/SAE unless it is an intentional overdose taken with possible 
suicidal/self- harming intent. Such overdoses should be reported regardless of 
sequelae.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 56Events NOT Meeting the AE Definition
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  the 
investigator to be more severe than expected for the participant’s condition.
The disease/disorder being studied or expected progression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital).
Anticipated day -to-day fluctuations of preexisting disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
10.3.2. Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious 
conditions are met (eg, hospitalization for signs/sy mptoms of the disease under study , death 
due to progression of disease).
An SAE is defined as any untoward medical occurrence that, at any dose:
a.Results in death
b.Is life -threatening
The term “life-threaten ing”in the definition of “serious” refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event that
hypothetically  might have caused death if it were more severe.
c.Requires inpatient hospitalization or prolongation of existing hospitalization
In general, hospitalization signifies that the participant has been detained (usually 
involving at least an overnight stay ) at the hospital or emergency  ward for observation 
and/or treatment that would not have been appropriate in the ph ysician’s office or 
outpatient setting. Complications that occur during hospitalization are AEs. If a 
complication prolongs hospitalization or fulfills any other serious criteria, the event is 
serious. When in doubt as to 
whether “hospitalization” occurred or was necessary , the AE 
should be considered serious.
Hospitalization for elective treatment of a preexisting condition that did not worsen from 
baseline is not considered an AE.
d.Results in persistent disability /incapac ity
The term disability means a substantial disruption of a person’s ability  to conduct 

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 5710.3.3. Recording/Reporting and Follow -up of AE sand/or SAE s
AE and SAE Recording /Reporting
The ta ble below summarizes the requirements for recording adverse events on the CRF and 
for reporting serious adverse events on the Clinical Trial (CT) Serious Adverse Event 
(SAE) Report Form to Pfizer Safety .  These requirements are delineated for 3 types of 
events: (1) SAEs; (2) nonserious adverse events (AEs); and (3) exposure to the IPunder 
study  during pregnancy  or breastfeeding, and occupational exposure. 
It should be noted that the CT SAE Report Form for reporting of SAE information is not 
the same as th e AE page of the CRF.  When the same data are collected, the forms must be 
completed in a consistent manner.  AEs should be recorded using concise medical 
terminology  and the same AE term should be used on both the CRF and the CT SAE 
Report Form for report ing of SAE information.
Safety Event Recorded on the CRF Reported on the CT SAE 
Report Form to Pfizer 
Safety  Within 24 Hours of 
Awareness
SAE All All
Nonserious AE All Nonenormal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma (eg, sprained ankle) which may  interfere with or 
prevent every day life functions but do not constitute a substantial disruption.
e.Is a congenital anomal y/birth defect
f.Other situations:
Medical or scientific judg ment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as important medical events that 
may not be immediatel y life-threatening or result in death or hospitalization but 
may jeopardize the participant or may  requ ire medical or surgical intervention to 
prevent one of the other outcomes listed in the above definition. These events 
should usually  be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospitalization, or development of drug 
dependency  or drug abuse.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 58Exposure to the 
investigational product 
under study  during 
pregnancy  or 
breastfe eding, and 
occupational exposureNone All (and exposure during 
pregnancy  [EDP ]
supplemental form for 
EDP)  
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (eg, hospital progress notes, laboratory reports, a nd diagnostic 
reports) related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is not acceptable for the investigator to send photocopies of the participant’s 
medical records to Pfizer Safety  in lieu of comple tion of the CT SAE Report 
Form /AE/SAE CRF page.
There may  be instances when copies of medical records for certain cases are 
requested b y Pfizer Safety .In this case, all participant identifiers, with the 
exception of the participant number, will be redact ed on the copies of the medical 
records before submission to Pfizer Safety .
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individu al signs/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easil y tolerated by  the participant, causing minimal 
discomfort and not interfering with every day activities.
Moderate: An event that causes sufficient discomfort and interferes with normal 
every day activities.
Severe: An event that prevents normal every day activities. An AE that is assessed 
as severe should not be confused with a nSAE.  Severe is a category  utilized for 
rating the intensit y of an event; and both AEs and SAEs can be assessed as severe.
An event is defined as “serious” when it meets at least 1 of the predefined outcomes 
as described in the definition of an SAE, NOT when it is rated as severe.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 59Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE.
A “reasonable possibility” of a relationship convey s that there are facts, evidence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment to determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
The investigator will also consult the investigator’s brochure (IB) and/or p roduct 
i
nformation, for marketed products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provided an assessment of causality .
There may be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the Sponsor .However, it is 
very important that the investigator alway s make an assessment of causality for 
every  event before the initial transmission of the SAE data to the Sponsor .
The investigator may  change his/her opinion of causality  in light of follow -
up 
information and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of t he criteria used when determining regulatory  
reporting requirements.
If the investigator does not know whether or not the IPcaused the event, then the 
event will be handled as “related to IP” for reporting purposes, as defined by  the 
Sponsor .  In addition , if the investigator determines that an SAE is associated with 
study  procedures, the investigator must record this causal relationship in the source 
documents and CRF, and report such an assessment in the dedicated section of the 
CT SAE Report Form and in accordance with the SAE reporting requirements.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 60Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically  indicated or as requested by  the 
Sponsor to eluci date the nature and/or causalit y of the AE or SAE as full y as 
possible. This may  include additional laboratory  tests or investigations, 
histopathological examinations, or consultation with other healthcare professionals.
If a participant dies during parti cipation in the study  or during a recognized 
follow -up period, the investigator will provide Pfizer Safet y with a cop y of any 
postmortem fin
dings including histopathology .
New or updated information will be recorded in the originally  completed CRF.
The investigator will submit any  updated SAE data to the Sponsor within 24 hours 
of receipt of the information.
10.3.4. Reporting of SAEs
SAE Reporting to Pfizer Safety via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to Pfizer Safety will be the electronic 
data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours.
The site will enter the SAE data into the elect ronic sy stem as soon as the data
become available.
After the stud y is completed at a given site, the electronic data collection tool will 
be taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SAE form (see 
next section) or to Pfizer Safety  by telephone.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 61SAE Reporting to Pfizer Safety via CT SAE Report Form
Facsimile transmission of the CT SAE Report Form is the preferred method to 
transmit this information to Pfizer Safety .
In circumstances when the facsimile is not working , notification by  telephone is 
acceptable with a cop y of the CT SAE Report Form sent by  overnight mail or 
courier service.
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the CT SAE Report Form pages within the designated reporting 
time frames.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 6210.4. Appendix 4: Contraceptive Guidance and Collection of Pregnancy Information
10.4.1. Male Participant Reproductive Inclusion Criteria
Male participants are eligible to participate if they  agree to the following requirements during 
the interve ntion period and for at least 3 weeks after the last dose of study  intervention ,
which corresponds to the time needed to eliminate study  intervention(s) (eg, 5 terminal 
half-lives) plus an additional 90 days (a spermatogenesis cy cle): 
Refrain from donatin g sperm .
PLUS either:
Be abstinent from heterosexual or homosexual intercourse as their preferred and usual 
lifesty le (abstinent on a long -term and persistent basis) and agree to remain abstinent ;
OR
Must agree to use contraception/barrier as detailed bel ow:
Agree to use a male condom when engaging in any activity  that allows for 
passage of ejaculate to another person .
Use of an additional highly  effective contraceptive method with a failure rate of 
<1% per year as described below in Section 10.4.4 for a female partner of 
childbearing potential.
10.4.2. Female Participant Reproductive Inclusion Criteria
A female participant, not a WOCBP (see definitions below in Section 10.4.3), is eligible to 
participate .
The investigator is responsible for review of medical history , menstrual history , and recent 
sexual activity  to decrease the risk for inclusion of a woman with an earl y undetected 
pregn ancy . 
10.4.3. Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming postmenopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before the 
first dose of study  intervention, additional evaluation should be 
considered.
Women in the following categories are not considered WOCBP:
1.Premenarchal .

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 632.Premenopausal female with 1 of the following:
Documented h ysterectom y;
Documented bilateral salpingectomy ;
Documented bilateral oophorectom y.
For individuals with permanent infertility  due to an alternate medical cause other than 
the above, (eg, mullerian agenesis, androgen insensitivity ), investigator discretion 
should be applied to determining study  entry .
Note: Documentation for any  of the above categories can come from the site 
personnel’s review of the participant’s medical records, medical examination, or 
medical history  interview.  The method of documentation should be recorded in the 
participant’s medical record for the stud y.
3.Postmenopausal female .
A postmenopausal state is defined as age 60 yearsor older or no menses for 
12months without an alternative medical cause. 
A high follicle -stimulating hormone (FSH) level in the postmenopausal range 
may be used to confirm a postmenopausal state in women not using hormonal 
contraception or hormon ereplacement therap y (HRT). 
Females on HRT and whose menopausal status is in doubt will be required to 
use one of the nonestro gen hormonal highl y effective contraception methods 
if they  wish to continue their HRT during the study .  Otherwise, they  must 
discontinue HRT to allow confirmation of postmenopausal status before study  
enrollment.
10.4.4. Contracepti onMethods
Highl y Effective Me thods That Have Low User Dependen cy
1.Implantable progestogen -only hormone contraception associated with inhibition of 
ovulation
.
2.Intrauterine device (IUD) .
3.Intrauterine hormone -releasing s ystem (IUS) .
4.Bilateral tubal occlusion .

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 645.Vasectomized partner .
Vasect omized partner is a highl y effective contraceptive method provided that the 
partner is the sole sexual partner of the WOCBP and the absence of sperm has 
been confirmed. If not, an additional highl y effective method of contraception 
should be used. The s permatogenesis cy cle is approximately  90days.
Highl y Effective Methods 
That Are User Dependent 
1.Combined (estrogen- and progestogen -containing) hormonal contraception associated 
with inhibition of ovulation .
Oral;
Intravaginal;
Transdermal ;
Injectable .
2.Progestogen -only hormone contraception associated with inhibition of ovulation .
Oral;
Injectable .
3.Sexual abstinence .
Sexual abstinence is considered a highl y effective method only  if defined as 
refraining from heterosexual intercourse during the entire period of risk associated 
with the study  intervention.   The reliability  of sexual abstinence needs to be 
evaluated in relation to the duration of the stud y and the preferred and usual 
lifesty le of the participant.
Collection of Pregnancy Information
For both una pproved/unlicensed products and for marketed products, an exposure during 
pregnancy  (EDP) occurs if:
A female becomes, or is found to be, pregnant either while receiving or having been 
exposed (eg, because of treatment or environmental exposure) to the IP;or the female 
becomes or is found to be pregnant after discontinuing and/or being exposed to the 
IP;

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 65An example of environmental exposure would be a case involving direct contact 
with a Pfizer product in a pregnant woman (eg, a nurse reports that she is p regnant 
and has been exposed to chemotherapeutic products).
A male has been exposed (eg, because of treatment or environmental exposure) to the 
IPprior to or around the time of conception and/or is exposed during his partner’s 
pregnancy .
If a participant or participant ’s partner becomes or is found to be pregnant during the 
participant ’s treatment with the IP, the investigator must report this information to Pfizer 
Safety  on the CT SAE Report Form and an EDP supplemental form, regardless of whether an 
SAE has occurred.  In addition, the investigator must submit information regarding 
environmental exposure to a Pfizer product in a pregnant woman (eg, a participant reports 
that she is pregnant and has been exposed to a cy totoxic product by  inhalation or spill age) to 
Pfizer Safety  using the EDP supplemental form.  This must be done irrespective of whether 
an AE has occurred and within 24 hours of awareness of the exposure.  The information 
submitted should include the anticipated date of delivery  (see below for information related 
to termination of pregnancy ).
Follow -up is conducted to obtain general information on the pregnancy  and its outcome for 
all EDP reports with an unknown outcome.  The investigator will follow the pregnancy  until 
completion (or until pre gnancy  termination) and notify  Pfizer Safet y of the outcome as a 
follow -up to the initial EDP supplemental form.  In the case of a live birth, the structural 
integrit y of the neonate can be assessed at the time of birth.  In the event of a termination, the
reason(s) for termination should be specified and, if clinically  possible, the structural 
integrit y of the terminated fetus should be assessed by gross visual inspection (unless 
preprocedure test findings are conclusive for a congenital anomal y and the fi ndings are 
reported).
If the outcome of the pregnancy  meets the criteria for an SAE (ie, ectopic pregnancy , 
spontaneous abortion, intrauterine fetal demise, neonatal death, or congenital anomal y [in a 
live-born bab y, a terminated fetus, an intrauterine fet al demise, or a neonatal death]), the 
investigator should follow the procedures for reporting SAEs.
Additional information about pregnancy  outcomes that are reported to Pfizer Safet y as SAEs 
follows: 
Spontaneous abortion includes miscarriage and missed ab ortion;
Neonatal deaths that occur within 1 month of birth should be reported, without regard 
to causality , as SAEs.  In addition, infant deaths after 1 month should be reported as 
SAEs when the investigator assesses the infant death as related or possibly related to 
exposure to the IP. 

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 66Additional information regarding the EDP may  be requested by  the Sponsor .  Further 
follow -up of birth outcomes will be handled on a case- by-case basis (eg, follow -up on 
preterm infants to identify developmental delay s).  Inthe case of paternal exposure, the 
investigator will provide the participant with the Pregnant Partner Release of Information 
Form to deliver to his partner.  The investigator must document in the source documents that 
the participant was given the Pregna nt Partner Release of Information Form to provide to his 
partner.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 6710.5. Appendix 5: Genetics
Use/Anal ysis of DNA
Genetic variation may  impact a participant’s response to study  intervention, 
susceptibility  to, and severity  and progression of disease. Therefore, where local 
regulations and IRB s/ECsallow, a blood sample will be collected for DNA anal ysis.
Genetic research may  consist of the analy sis of 1 or more candidate genes or the 
analysis of genetic markers throughout the genome or anal ysis of the entire geno me 
(as appropriate).
The samples may  be analy zed as part of a multistudy  assessment of genetic factors 
involved in the response to dacomitinib or study  interventions of this class to 
understand treatments for the disease(s) under study  or the disease(s) themselves.
The results of genetic analy ses may  be reporte d in the CSR or in a separate study  
summary , or may  be used for internal decision making without being included in a 
study  report.
The Sponsor will store the DNA samples in a secure storage space with adequate 
measures to protect confidentiality . 
The samples will be retained as indicated:
Samples for specified genetic anal ysis (see Section 8.7) will be stored for up to 
1years or other pe riod as per local requirements or will not be stored bey ond the 
completion of this study  (eg,CSR finalization)].
Samples for banking (see Section 8.7.2) will be stored indefinitel y or other p eriod 
as per local requirements. 
Participant s may  withdraw their consent for the storage and/or use of their banked 
biospecimens at an y time by  making a request to the investigator; in this case, any  
remaining material will be destro yed.  Data already gen erated from the samples will 
be retained to protect the integrit y of existing analyses. 
Banked biospecimens will be labeled with a code.  The key  between the code and the 
participant ’s personally  identify ing information (eg ,name, address) will be held at the 
study  site and will not be provided to the sample bank. 

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 6810.6. Appendix 6: Liver Safety: Suggested Actions and Follow- up Assessments
Potential Cases of Drug- Induced Liver Injury
Humans exposed to a drug who show no sign of liver injury  (as determined by  elevations in 
transaminases) are termed “tolerators,” while those who show transient liver injury , but adapt 
are termed “adaptors.”  In some participant s, transaminase elevations are a harbinger of a 
more serious potential outcome.  These participant s fail to adapt and therefore are 
“susceptible” to progressive and serious liver injury , commonl y referred to as drug -induced 
liver injury  (DILI).  Participant s who experience a transaminase elevation above 3 times the 
upper limit of normal (× ULN) should be monito red more frequentl y to determine if they  are 
an “adaptor” or are “susceptible.”
In the majority  of DILI cases, elevations in aspartate aminotransferase (AST) and/or alanine 
aminotransferase (ALT) precede total bilirubin (Tbili) elevations (>2 × ULN) by  several day s 
or weeks.  The increase in T
bili ty pically  occurs while AST/AL T is/are still elevated above 
3
×ULN (ie, AST/ALT and Tbili values will be elevated within the same lab oratory sample).  
In rare instances, b y the time T bili elevations are detected, AST/ALT values might have 
decreased.  This occurrence is still regarded as a potential DILI.  Therefore, abnormal 
elevations in either AST OR AL T in addition to T bili that meet the criteria outlined below 
are considered potential DILI (assessed per Hy ’s law criteria) cases and should alway s be 
considered important medical events, even before all other possible causes of liver injury 
have been excluded.
The threshold of laboratory  abnormalities for a potential DILI case depends on the 
participant ’s individua l baseline values and underly ing conditions.  Participant s who present 
with the following laboratory  abnormalities should be evaluated further as potential DILI 
(Hy’s law) cases to definitively  determine the etiology  of the abnormal laboratory  values:
Participant s with AST/ALT and T bili baseline values within the normal range who 
subsequently  present with AST OR AL T values >3 × ULN AND a Tbili value 
>2×
ULN with no evidence of hemol ysis and an alkaline phosphatase value 
<2×ULN or not available.
For participant s with baseline AST OR ALT OR T bili values above the ULN, the 
following threshold values are used in the definition mentioned above, as needed, 
depending on which values are above the ULN at baseline:
Preexisting AST or ALT baseline values above the normal range: AST or ALT 
values >2 times the baseline values AND >3 ×
ULN; or >8 × ULN (whichever is 
smaller).
Preexisting values of T bili above the normal range: T bili level increased from 
baseline value b y an amount of at least 1 × ULN or if the value re aches >3 ×ULN 
(whichever is smaller).

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 69Rises in AST/AL T and T bili separated by more than a few weeks should be assessed 
individually  based on clinical judgment; any  case where uncertainty  remains as to whether it 
represents a potential Hy’s law case should be reviewed with the Sponsor . 
The participant should return to the investigator site and be evaluated as soon as possible, 
preferabl y within 48 hours from awareness of the abnormal results.  This evaluation should 
include laboratory  tests, detailed histo
ry, and physical assessment. 
In addition to repeating measurements of AST and AL T and T bilifor suspected cases of 
Hy’s law, additional laboratory  tests should include albumin, creatine kinase (CK), direct and 
indirect bilirubin, gamma -glutam yl transferas e (GGT), prothrombin time (PT)/international 
normalized ratio (INR), total bile acids, and alkaline phosphatase.  Consideration should also 
be given to drawing a separate tube of clotted blood and an anticoagulated tube of blood for 
further testing, as nee ded, for further contemporaneous anal yses at the time of the recognized 
initial abnormalities to determine etiology .  A detailed history , including relevant 
information, such as review of ethanol, acetaminophen (either b y itself or as a coformulated 
produc t in prescription or over
-the-counter medications) , recreational drug, supplement 
(herbal) use and consumption, family  history , sexual history , travel history, history  of contact 
with a jaundiced person, surgery , blood transfusion, history  of liver or alle rgic disease, and 
potential occupational exposure to chemicals, should be collected.  Further testing for acute 
hepatitis A, B, C, D, and E infection and liver imaging (eg, biliary  tract) and collection of 
serum sample for acetaminophen drug and/or protein adduct levels may be warranted. 
All cases demonstrated on repeat testing as meeting the laboratory  criteria of AST/AL T and 
T
bili elevation defined above should be considered potential DILI (Hy ’s law) cases if no 
other reason for the liver function test ( LFT)abnormalities has y et been found.  Such 
potential DILI (Hy ’s law) cases are to be reported as SAEs, irrespective of availability  of all 
the results of the investigations performed to determine etiology  of the LFT abnormalities. 
A potential DILI (Hy ’slaw) case becomes a confirmed case onl y after all results of 
reasonable investigations have been received and have excluded an alternative etiology .

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 7010.7. Appendix 7: ECG Findings of Potential Clinical Concern
ECG Findings That May Qualify as Adverse Events (AEs)
Marked sinus brad ycardia (rate <40 bpm) lasting minutes.
New PR interval prolongation >280 msec.
New prolongation of QTcF to >480 msec(absolute) or b y 60msecfrom baseline .
New -onset atrial flutter or f ibrillation, with controlled ventricular respon se rate: ie, 
rate<120 bpm.
New -onset t ypeI second -degree (Wenckebach) AV block of >30 seconds’
duration.
Frequent premature ventricular complexes (PVCs), triplets, or short intervals 
(<30 seconds) of consecutive ventricular complexes.
ECG Findings That May Qualify as Serious Adverse Events (SAE s)
QTcF prolongation >500 msec.
New ST- T changes suggestive of my ocardial ischemia .
New -onset l eft bundle branch block (QRS complex >120 msec).
New -onset right bundle b ranch block (QRS complex >120 msec ).
Symptoma tic bradycardia .
Asystole:
In awake, s ymptom -free participant s in sinus rhy thm, with documented periods 
of as ystole  3.0seconds or an y escape rate <40 bpm, or with an escape rhy thm 
that is below the AV node. 
In awake, s ymptom -free participant s with atri al fibrillation and brad ycardia 
with 1 or more pauses of at least 5 seconds or longer. 
Atrial f lutter or fibrillation, with rapid ventricular response rate: rapid = rate 
>120 bpm.
Sustained s upraventricular tachycardia (rate >120 bpm) ( “sustained ”= short
duration with relevant s ymptoms or lasting >1 minute) .
Ventricular r hythms >30 seconds ’duration, including idioventricular rhy thm (rate 
<40bpm), accelerated idioventricular rh ythm (40< x <100) ,and 

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 71monomorphic/poly morphic ventricular tachy cardia >100 bpm (such as torsades de 
pointes) .
Type II second -
degree (Mobitz II) AV block.
Complete (third
-degree) heart block.
ECG Findings That Qualify as Serious Adverse Events
Change in pattern suggestive of new m yocardial infarction .
Sustained ventricular t achy arrhythmias (>30 seconds ’duration) .
Second- or third -degree AV block requiring pacemaker placement.
Asystolic pauses requiring pacemaker placement.
Atrial flutter or fibrillation with rapid ventricular response requiring cardioversion .
Ventricular fibrilla tion/flutter .
At the discretion of the investigator, an y arrh ythmia classified as an adverse 
experience .
The enumerated list of major events of potential clinical concern are recommended as “alerts ”or 
notifications from the core ECG lab oratory to the inv estigator and Pfizer study team ,and not to be 
considered as all inclusive of what to be reported as AEs/SAEs.

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 7210.8. Appendix 8:Modified Child -Pugh Classification (CPC) of Liver D ysfunction
CPC score is calculated from the sum of the points for each CPC crite ria:
CPC Classification Level of dysfunction Score
C Severe 10
Assessment Param eters Assigned Score for O bserved Findings
1 point 2 point 3 point
Encephalopathy grade
(refer to table below )0 1 or 2 3 or 4a
Ascites Absent Slight Moderateb
Serum total bilirubin, mg/dL <2 2 to 3 >3
Serum albumin, g/dL >3.5 2.8 to 3.5 <2.8
Prothrombin time , seconds prolonged <4 4 to 6 >6
a.Including participant s with a history of stage 3 or stage 4 encephalopathy receiving medication(s) to 
prevent recurrent encephal opathy; participant s with clinically active stage 3 or 4 encephalopathy are 
excluded from participation in the study.
b.Including participant s with history of severe ascites on medication(s) to control their ascites.
Encephalopathy 
GradeDefinition
0 Norm al consciousness, personality, neurological exam
1 Restless, sleep disturbed, irritable/agitated, tremor, impaired handwriting
2 Lethargic, time -disoriented, inappropriate, asterixis, ataxia
3 Somnolent, stuporous, place- disoriented, hyperactive reflexe s, rigidity
4 Unrousable coma, no personality/behavior, decerebrate

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 7310.9. Appendix 9: Abbreviations
The following is a list of abbreviations that may  be used in the protocol.
Abbreviation Term
%CV percent coefficient of variation
abs absolute
ADME absorpt ion, distribution, metabolism and excretion
AE adverse event
Akt protein kinase b
ALK anaplastic lymphoma kinase
ALP alkaline phosphatase
ALT alanine aminotransferase
ANOVA analysis of variance
AST aspartate aminotransferase
ATP adenosine triphosph ate
AUC 24 area under the concentration time curve from time 0 to 24 hours post -dose
AUC inf area under the concentration time curve from time 0 to infinity
AUC inf, u unbound AUC inf
AUC last area under the concentration time curve from time 0 to the time of last quantifiable 
concentration
AUC last, u unbound AUC last
AUC tau area under the concentration time curve over doing interval tau
BBS Biospecimen Banking System
BCRP breast cancer resistance protein
BMI body mass index
BP blood pressure
bpm beats per minute
BSEP bile salt export pump
BUN blood urea nitrogen
CBER Center for Biologics Evaluation and Research
CDER Center for Drug Evaluation and Research
CK creatine kinase
Cmax maximum observed plasma concentration
Cmax, u unbound C max
CFR Code of Federal Regulation s
CI confidence interval
CIOMS Council for International Organizations of Medical Sciences
CL clearance
CL/F apparent oral clearance
CL u/F unbound CL/F
CPC Child- Pugh Classification
CRF case report form
CRO contract research organization
CRU clinical research unit
CSR clinical study report
CT clinical trial
CTMS clinical trial management system
CYP cytochrome P450
DCT data collection tool
DDI drug-drug interaction
DILI drug-induced liver injury

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 74Abbreviation Term
DMC data monitoring com mittee
DNA deoxyribonucleic acid
DRE disease -related event
DU dispensable unit
EC ethics committee
ECG Electrocardiogram
eCRF electronic case report form
E-DMC external data monitoring committee 
EDP exposure during pregnancy
EGFR epidermal grow thfactor receptor
eGFR estimated glomerular filtration rate
EM extensive metabolizer
EMA European Medicines Agency
EU European Union
EudraCT European Clinical Trials Database
FDA Food and Drug Administration
FSH follicle -stimulating hormone
fu fraction of unbound drug in plasma
GCP Good Clinical Practice
GGT gamma -glutamyl transferase
GI gastrointestinal
HepBcAb hepatitis B core antibody
HepBsAg hepatitis B surface antigen
HCVAb hepatitis C antibody
HIPAA Health Insurance Portability and Acco untability Act
HIV human immunodeficiency virus
HRT horm one replacement therapy
IB investigator’s brochure
ICD informed consent document
ICH International Council for Harmonisation
ID identification
IGF1R insulin -like growth factor 1 receptor
IM intermediate metabolizer
IND investigational new drug
INR international normalized ratio
IP investigational product 
IRB institutional review board
IRC internal review committee
IRT interactive response technology
IUD intrauterine device
IUS intraut erine hormone -releasing system
IV intravenous
JAK3 janus kinase 3
K2EDTA dipotassium ethylenediamine tetraacetic acid
LFT liver function test
MDRD Modification of Diet in Renal Disease
MET mesenchymal -epithelial transition
MRI magnetic resonance ima ging
N/A not applicable
NCI National Cancer Institute

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 75Abbreviation Term
NSCLC non-small cell lung cancer
OAT organic anion transporter
OATP organic anion transporting polypeptide
OCT organic cation transporter
PCD primary completion date
PD pharmacodynamic(s)
PDGFR platelet -derived growth factor receptor
PGx pharmacogenomic(s)
P-gp P-glycoprotein
PI principal investigator
PI3K phosphoinositide 3 -kinase
PK pharmacokinetic(s)
PPI proton -pump inhibitor
PR pulse rate
PT prothrombin time
QD once daily
QTc corrected QT
QTcB corrected QT (Bazett method)
QTcF corrected QT (Fridericia method)
qual qualitative
RBC red blood cell
RNA ribonucleic acid
ROS1 ROS oncogene 1
RTK receptor tyrosine kinase
rCYP recombinant cytochrom e P450
SAE serious adverse event
SAP statistical analysis plan
SCr serum creatinine
SoA schedule of activities
SOP standard operating procedure
SRSD single reference safety document
SToD study team on demand
SUSAR suspected unexpected serious adverse reaction
t½ terminal phas e half -life
Tbili total bilirubin
TIPS transjugular intrahepatic portosystemic shunt
Tmax time to reach the maximum observed plasma concentration
UGT uridine diphosphate glucuronosyltransferase
ULN upper limit of normal
US United States
Vz/F apparent volu me of distribution
Vz, u/F Unbound V z/F
WBC white blood cell
WOCBP woman of childbearing potential

Dacom itinib
A7471058
Final Protocol, 14 November 2018
Page 7611.REFERENCES
1. Banholzer ML, Wandel C, Barrow P, et al. Clinical trial considerations on male 
contraception and collection of pregnancy  information from fem ale partner: update. 
Clin Tran slMed 2016;5 (1):23- 37.
2. T he National Cancer Institute Organ Dy sfunction Working Group Criteria for 
assessment of hepatic impairment .
3. FDA Guidance for Industry : Pharmacokinetics in Patients with I mpaired Hepatic 
Function: Study Design, Data Anal ysis, and Impact on Dosing and Labeling (Issued by  
CDER/CBER, May  2003).
